What will be the biggest scientific breakthrough of 2020? – Stuff.co.nz

Cheap, re-purposed cancer drugs, negative carbon-emissions technology, calculating how fast the universe is expandingand huge leaps forward in quantum computing.

Will one of these be the biggest scientific breakthrough of 2020?

We asked a handful of New Zealand's top scientists what "Eureka!" moments might be on the cards next year but even with their formidable combined brain power and expertise, some found it hard to answer and hinted it was difficult to sheet home specific advances to any one year.

And, as one scientist says, 2020's most ground-breaking discovery may come as a total surprise, made accidentally by a student in a lab late one night.

READ MORE:*Scientists are baffled: What's up with the universe?*Medicine already in use may help cancer treatments*Roger Hanson: How you figure out the age of the universe*Doing my part not only to be carbon neutral but carbon negative

123rf

2020's most ground-breaking discovery may come as a total surprise, made accidentally by a student in a lab late one night.

Wellington's Gillies McIndoe Research Institute is carrying out cutting-edge research into ways of treating cancer without radiotherapy, chemotherapy or surgery.

The institute's founder and executive director, Dr Swee Tan, believes significant steps will be made in 2020 towards "re-purposing" existing drugs for cancer treatment.

Tan, a plastic surgeon and medical researcher who has received international recognition for dealing with life-threatening and disfiguring conditions, saiddrugs licensed and marketed for a particular treatment often had other benefits.

"They can be re-purposed for another condition, for the treatment of cancer. This is usually with drugs that have been around for some time they are off-patent, so they become generic, which means they cost next to nothing.

"Another advantage is their safety profile is well understood."

Wellington's Gillies McIndoe Research Institute's founder and executive director, Dr Swee Tan, believes significant steps will be made in 2020 towards "re-purposing" existing drugs for cancer treatment.

Globally, 18 million new cancer cases are diagnosed each year, resulting in nearly 10 million deaths.

"In New Zealand alone, new cancer cases are about 25,000 a year, and on top of that there are 11,000 non-melanoma skin cancers.

"The incidence of cancer is predicted to increase by 50 per cent by 2035, which is just around the corner. We are completely unprepared for that."

The increased incidence of cancer largely bowel, breast, prostate and lung cancers, and melanoma is mostly because people are living longer and due to lifestyle and diet, Tan says.

"Part of the problem now is the expense of treatment. In New Zealand, we spend $1 billion a year to treat cancer, and that is just the fiscal cost, that doesn't count emotional or personal.

"The cost is escalating because of the novel cancer drugsand, at some point, we are not going to be able to afford treatment for cancer.

"This creates disparity in access to treatment because some of these drugs are not funded and, if you have the means, you can buy it, but I don't think that is a good way to run a society. I think a society should allow people to access healthcare, regardless of personal circumstance."

Royal Society Te Aprangi/VIMEO

New Zealand is as vulnerable as all countries to the global growth in antimicrobial resistance that is making some diseases untreatable. Dr Siouxsie Wiles, a microbiologist from the University of Auckland, a Royal Society Te Aprangi Councillor and an expert adviser on the report on antimicrobial resistance produced by Royal Society Te Aprangi explains why it is such a big issue for us.

The institute has been undertaking a clinical trial based on drug re-purposing to control cancer stem cells, the proposed origin of cancer.

"It consists of a combination of low-cost, off-patent, oral medications to control cancer stem cells. We believe this would be more effective than using a single drug.

"For the cost of the drug itself, it costs about $4000 a year a patient, compared with the average cancer treatment, which is about $50,000 per patient.

"You have to prove it is effective first. The big issue with drug re-purposing is 'big pharma' is not interested because there is no money in it. The only way that we can realise the potential is for philanthropy and government to support initiatives like this."

Propranolol, a beta-blocker, had been added to the treatment for melanoma and angiosarcoma.

During 2020, GMRI would also be working on treatments for disfiguring keloid scars.

"They can cause quite significant issues with quality of life. They affect about 2 per cent of the general population, but in dark-skinned races, especially from the African continent, incidence can be up to 16 per cent.

"Treatment is really quite unsatisfactory, hence the reason why we are researching a solution. If you do surgery to remove it, almost every single one returns. Sometimes surgery is followed by radiotherapy to prevent recurrence. Topical chemotherapy is also used.

"What we have found is stem cells as the underlying problem. We are doing further work, which may allow us to develop a simpler, more effective, low-cost treatment taken by mouth, or by applying to the keloid lesion directly."

University of Auckland molecular biologist Dr Hilary Sheppard, a specialist in developmental and stem-cell biology, thinks there will be more emphasis next year on the gene-editing of adult cells.

University of Auckland microbiologist,associate professor Siouxsie Wiles, a specialist in infectious diseases and antimicrobial resistance, says there are "desperately" needed breakthroughs in her field next year and beyond, including:

- Rapid "bedside" diagnostic tests that are cheap and can tell the medical practitioner if the patient has a bacterial or viral infection "a bonus if it can tell, if bacterial, what antibiotics would kill the bacterium responsible".

- Effective vaccines for tuberculosis, gonorrhoea, Staphylococcus aureus, Group A and B Streptococci, giardia "I could go on and on".

- Drugs that can kill carbapenemase-producing Enterobacteriaceae "a very scary group of organisms that are becoming untreatable".

"The other breakthroughs we need aren't scientific, they are political," she says.

"[We need] a global agreement on tackling antimicrobial resistance, which would include incentives to bring the pharmaceutical industry back in to antimicrobial development.

"Failing that, nationalisation of pharmaceutical companies so that development of drugs isn't a for-profit initiative."

Phil Doyle/Stuff

University of Auckland microbiologist, associate professor Siouxsie Wiles, says a global agreement on tackling antimicrobial resistance is desperately needed.

University of Auckland molecular biologist Dr Hilary Sheppard, a specialist in developmental and stem-cell biology, thinks there will be more emphasis next year on the gene-editing of adult cells.

"We have seen some major breakthroughs this year, such as the versatile tool which allows for gene-editing with increased precision over existing tools so the technique is becoming more reliable and safer. Hopefully, next year, we will see these newer techniques being tested in clinically relevant cells.

"As part of that, I hope we will see a community-wide discussion about the ethics of gene-editing with a particular focus on adult cells. Personally, I do not think we should be editing germline cells or embryos at least not for the next five years, while the ethical issues are debated.

"Part of gene-editing is knowing what DNA sequence needs to be edited, so I think I hope this could be the year where personalised medicine and individual genotyping takes off.

"Our research focuses on patients with a fragile skin condition called epidermolysis bullosa (EB). We are pushing to get patients with EB genotyped so that we can perform gene-editing on their skin cells we can't do anything useful without this information.

"Currently, we are paying for the genotyping out of our research budgets. Of course, genotyping raises its own ethical and societal issues, so I hope we will see more discussion about this."

In 2020, results should start rolling in from clinical trials using edited T-cells against melanoma and edited bone-marrow cells to treat patients with sickle-cell anaemia, Sheppard says.

"These are very exciting times. I'm sure we'll see more clinical trials targeting previously untargeted disorders soon perhaps for conditions like Duchenne muscular dystrophy and cystic fibrosis."

RNZ

In this podcast, The Detail's Sharon Brettkelly talks to Auckland University physics professor Shaun Hendy about his no-flying mission for the whole of last year.

While Tan, Sheppard and Wiles are looking for discoveries on the tiniest of scales, other scientists are grappling with the biggest question in the universe.

Theoretical cosmologist and University of Auckland professor of physics Richard Easther is among those hoping for a resolution of what has become known as "Hubble tension" a growing disagreement in calculations of how fast the universe is expanding, which has repercussions on its likely age.

The Hubble Constant the number that tells us how fast the universe was expanding has always been hard to measure, he says.

"There was a period of time when a whole different bunch of approaches to measuring it had converged on a single value, which is fascinating. But just over the last couple of years, it seems like there are now two different sets of numbers you get and they've pulled apart a little bit.

"You know, there's this joke that science isn't so much about people saying 'Eureka!' but about someone looking at something and going, 'well, you know, that's funny'.

"This is increasingly resembling one of those moments.

"The numbers are clustering around two values one that would put it in the early to mid-70s [kilometres per second per megaparsec], and one that would put it in the mid- to late 60s, and the uncertainty in the measurements is such that they don't really overlap with each other.

"As the individual measurements get more accurate, the sharpness of the disagreement is growing."

University of Auckland physicist, professor Shaun Hendy, is expecting leaps ahead in clean energy in 2020.

Does it matter? Of course, Easther says.

"There are different physical assumptions that go into the different measurementsandso, if there is a real discrepancy, it would tell us there's something about the expansion of the universe that we don't understand.

"It's hinting at that. The implication seems to be that the story is one step more complicated than current models of the expanding universe might recognise.

"One thought is, that in one set of numbers, there's something that got missed and kind of got away. The other possibility is, there's something kind of physical, that isn't included in our current thinking of the expanding universe.

"The idea that there is something interesting going on is something that cosmologists over the course of the last year have grown substantially more willing to entertain."

Chris Skelton/STUFF

Nicola Gaston is an Associate Professor in the Department of Physics at the University of Auckland and Co-Director of the MacDiarmid Institute for Advanced Materials and Nanotechnology.

At the University of Otago, associate professor Mikkel Andersen, a physicist in the university's Dodd-Walls Centre for Photonic and Quantum Technologies, has been making astounding international discoveries and controlling the movement of individual atoms in a world-first laboratory experiment.

Such control opens up possibilities for a "second quantum technology revolution" and quantum supremacy, something Andersen says will creep closer in 2020.

The first quantum revolution was made possible by the discovery of quantum mechanics in the 1920s, leading to the development of transistors and lasers, the building blocks of all computers.

In the second, he says quantum computers of fewer than 100 atoms will ultimately be able to out-compete "the world's combined conventional computing power".

"Reaching quantum supremacy means that a quantum computer will be able to do calculations that cannot be done on the world's conventional computers. I do not know if it will happen next year, but it will happen eventually.

"In recent years, Google, IBM, Microsoft and a lot of others have invested enormously in development of quantum computers. Quantum supremacy is likely still some years away, but it is one of those things that would clear all the headlines if it happened in 2020."

University of Auckland physicist,professor Shaun Hendy, agrees.

"Google declared quantum supremacy last month they demonstrated that a quantum computer could beat a conventional computer, albeit at a very niche task.

"We'll see more of this next year, as quantum computers start to stretch their legs just don't expect to see one on your phone any time soon."

Ross Giblin

Victoria University of Wellington's professor James Renwick hopes to see breakthroughs in climate change science which reduce greenhouse gas emissions.

Hendy is also expecting leaps ahead in clean energy in 2020.

"We will continue to see the cost of solar and battery technologies fall, to the extent that they will start to disrupt other energy systems. We have seen this already in Australia, where it has become a defining political issue.

"It will play out differently in New Zealand, because our grid is already more than 80 per cent renewable, while many of our industrial energy systems are not. Expect to see some of our big industrial corporates Fonterra, NZ Steel etc moving to greener industrial processes."

Victoria University of Wellington's Professor James Renwick, head of the school of geography, environment and earth sciences, hopes to see breakthroughs in climate change science which reduce greenhouse gas emissions.

He points to work being done at the Cawthron Institute in Nelson into the benefits of using the seaweed Asparagopsis armata as cattle feed. Chemicals in the red seaweed reduce microbes in the stomachs of cattle that make them burp when eating grass.

Renwick is also excited about the use of artificial intelligence (AI) and machine learning to help with severe weather prediction.

"Weather forecasters are totally inundated with information these days, volumes of radar data and satellite data coming through every 10 minutes. So, AI can help in making sense of all that, and what is the most important in determining where, for example, a severe storm will happen."

University of Otago associate professor Mikkel Andersen believes a "second quantum technology revolution" and quantum supremacy will creep closer in 2020.

Auckland University of Technology senior lecturer Dr Mahsa Mohaghegh also foresees huge steps forward in AI and its applications next year and beyond.

"In the medical sector, AI is being used to speed up symptom recognition and diagnosis. Early warning signs can be easily detected, allowing fast reaction.

"Environment and climate monitoring using AI can assist with weather-cycle predictions, frost warnings, and harvest alerts. Automated irrigation is possible using moisture and temperature sensors."

There are also uses in New Zealand's burgeoning space industry, in traffic management and in the "smart home" of the future, she says.

"New Zealand is a leader and frontrunner in the development of AI and related fields. The next 10 years of technology development are set to be exciting."

David White

Auckland University of Technology senior lecturer Dr Mahsa Mohaghegh foresees huge steps forward in AI and its applications next year.

University of Auckland physicist, associate professor Nicola Gaston, co-director of the Victoria University of Wellington-hosted MacDiarmid Institute for Advanced Materials and Nanotechnology, told Stuff scientific discovery did not happen "one year at a time".

"Discoveries that impact on our lives next year will be built on work that has been going on for decades. The biggest discoveries of next year will be the ones that impact on our lives in a decade or two.

"But there is no competition between this fundamental scientific work of discovery and the development of technologies. The two go in tandemand, perhaps in 2020, we can try to appreciate that."

That may be finding a way of moving to negative emissions technologies, or changing the chemistry of materials so they are recyclable and avoid environmental pollution.

"The most important breakthrough of 2020 will be one that none of us sees.

"It'll be a dedicated student or post-doc in a lab somewhere, or up late at night on a computer, who solves the last remaining piece of one of the puzzles that underpin so much of what we hope technology can do for us in the future."

Read more from the original source:
What will be the biggest scientific breakthrough of 2020? - Stuff.co.nz

A genetic study of 200,000 veterans with anxiety points toward potential new avenues for treatment – CNN

The genome-wide association study was the "largest ever study" looking into genes that could be associated with anxiety, according to Daniel Levey, a postdoctorate associate at the Yale School of Medicine and one of the authors of the study.

Levey's research group focused on 199,611 veterans in the data that had a continuous trait for anxiety based on a diagnostic scale for Generalized Anxiety Disorder.

Although anxiety is common across the human condition, Levey said "some people experience it in a way that becomes pathological."

Generalized Anxiety Disorder can manifest often in those who've experienced trauma while waging war far from home and looking at the genetic traits of veterans it affects can help the population as a whole.

They cast a wide net and came up with a few gems

Levey said having a "very large cohort is very effective" and the Veterans Affairs program is "one of the richest resources in the world" for data linking anxiety and genetics.

He noted that the veteran's data bank is valuable because of its racial diversity. Similar large-scale studies like this have been hamstrung by too many participants coming from a similar background, oftentimes only those with European ancestry.

In this most recent study, the researchers found that veterans of European descent had five genes that could be associated with anxiety.

One of the most useful findings was an association between anxiety and a gene named MAD1L1. In previous genome-wide association studies, MAD1L1 had shown indicated vulnerability to several other psychiatric conditions, including bipolar disorder and schizophrenia.

"It keeps coming up over and over again," Levey said.

They also identified a gene connected to estrogen. Levey said that potential estrogen link was important because this veteran cohort was 90% male, and that particular hormone is often associated with women.

For African Americans, the researchers identified a gene associated with intestinal functions that was potentially linked to anxiety.

"That gene variant doesn't exist outside African populations," Levey said.

The goal is to pinpoint more targeted treatments

Results like these could lead to more specific studies on each of the genes identified to determine how exactly they might be linked to anxiety and other psychological disorders. If further scrutiny of the genes reinforces the study's conclusions, that could lead to pharmaceutical research targeting how these genes operate.

Levey said he hoped that the study could lead to even more proactive outcomes, including early genetic testing to determine someone's susceptibility to anxiety. Individuals could then receive therapy to learn positive coping and stress management techniques even before symptoms began to surface, he said.

"We're making a lot of progress in genetics into what causes these conditions and how we might approach treatment," he said.

Continue reading here:
A genetic study of 200,000 veterans with anxiety points toward potential new avenues for treatment - CNN

Evenings with Genetics: "Connecting the Dots: Genes and Obesity" – TMC News – Texas Medical Center News

Evenings with Genetics is a regular seminar series hosted by Baylor College of Medicine and Texas Childrens Hospital. This seminar will discuss the diagnosis and medical management of genetic disorders of obesity. The audience will hear from a panel of speakers including Dr. Claudia Soler-Alfonso, assistant professor of molecular and human genetics at Baylor College of Medicine, Dr. Stephanie Sisley, assistant professor of pediatrics-nutrition at Baylor College of Medicine, and a guest parent speaker. The event is free and open to the public, but registration is required.

Read the original:
Evenings with Genetics: "Connecting the Dots: Genes and Obesity" - TMC News - Texas Medical Center News

Scientists pursue new genetic insights for health: Inside the world of deep mutational scanning – GeekWire

Jesse Bloom, left, and Lea Starita are genetic scientists pursuing advances with the technique known as Deep Mutational Scanning, which will be the subject of a symposium and workshop at the University of Washington in Seattle on Jan. 13 and 14. (GeekWire Photo / Todd Bishop)

It has been nearly two decades since scientists accomplished the first complete sequencing of the human genome. This historic moment gave us an unprecedented view of human DNA, the genetic code that determines everything from our eye color to our chance of disease, unlocking some of the biggest mysteries of human life.

Twenty years later, despite the prevalence of genetic sequencing, considerable work remains to fulfill the promise of these advances to alleviate and cure human illness and disease.

Scientists and researchers are actually extremely good at reading genomes, but were very, very bad at understanding what were reading, said Lea Starita, co-director of Brotman Baty Institute for Precision Medicines Advanced Technology Lab, and research assistant professor in the Department of Genome Sciences at the University of Washington.

But that is changing thanks to new tools and approaches, including one called Deep Mutational Scanning. This powerful technique for determining genetic variants is generating widespread interest in the field of genetics and personalized medicine, and its the subject of a symposium and workshop on Jan. 13 and 14 at the University of Washington.

I think approaches like Deep Mutational Scanning will eventually allow us to make better countermeasures, both vaccines and drugs that will help us combat even these viruses that are changing very rapidly said Jesse Bloom, an evolutionary and computational biologist at the Fred Hutchinson Cancer Research Center, the Howard Hughes Medical Institute and the University of Washington Department of Genome Sciences.

Bloom, who researches the evolution of viruses, will deliver the keynote at the symposium, held by the Brotman Baty Institute and the Center for the Multiplex Assessment of Phenotype.

On this episode of the GeekWire Health Tech Podcast, we get a preview and a deeper understanding of Deep Mutational Scanning from Bloom and Starita.

Listen to the episode above, or subscribe in your favorite podcast app, and continue reading for an edited transcript.

Todd Bishop: Lets start with the landscape for precision medicine and personalized medicine. Can you give us a laypersons understanding of how personalized medicine differs from the medicine that most of us have encountered in our lives?

Lea Starita: One of the goals of precision medicine is to use the genomic sequence, the DNA sequence of the human in front of the doctor, to inform the best course of action that would be tailored to that person given their set of genes and the mutations within them.

TB: Some people in general might respond to certain treatments in certain ways and others might not. Today we dont know necessarily why thats the case, but personalized medicine is a quest to tailor the treatment or

Starita: To the individual. Exactly. Thats kind of personalized medicine, but you could also extend that to infectious disease to make sure that youre actually treating the pathogen that the person has, not the general pathogen, if you would. How would you say that, Jesse?

Jesse Bloom: I would elaborate on what Lea said when it comes to infectious diseases and other diseases. Not everybody gets equally sick when they are afflicted with the same underlying thing, and people tend to respond very differently to treatments. That obviously goes for genetic diseases caused by changes in our own genes like cancer, and it also happens with infectious diseases. For instance, the flu virus. Different people will get flu in the same year and some of them will get sicker than others, and thats personalized variation. Obviously wed like to be able to understand what the basis of that variation is and why some people get more sick in some years than others.

TB: Where are we today as a society, as a world, in the evolution of personalized medicine?

Starita: Pretty close to the starting line still. Theres been revolutions in DNA sequencing, for example. Weve got a thousand dollar genome, right? So were actually extremely good at reading genomes, but were very, very bad at understanding what were reading. So you could imagine youve got a human genome, its three billion base pairs times two, because youve got two copies of your genome, one from your mother, one from your father, and within that theres going to be millions of changes, little spelling mistakes all over the genome. We are right now very, very, very I cant even use enough verys bad at predicting which ones of those spelling mistakes are going to either be associated with disease or predictive of disease, even for genes where we know a lot about it. Even if that spelling mistake is in a spot in the genome we know a lot about, say breast cancer genes or something like that, we are still extraordinarily bad at understanding or predicting what effects those changes might have on health.

Bloom: In our research, were obviously also interested in how the genetics of a person influences how sick they get with an infectious disease, but we especially focus on the fact that the viruses themselves are changing a lot, as well. So theres changes in the virus as well as the fact that were all genetically different and those will interact with each other. In both cases, it really comes back to what Lea is saying is that I think weve reached the point in a lot of these fields where we can now determine the sequences of a humans genome or we can determine the sequence of a virus genome relatively easily. But its still very hard to understand what those changes mean. And so, thats really the goal of what were trying to do.

TB: What is deep mutational scanning in this context?

Lea Starita: A mutation is a change in the DNA sequence. DNA is just As, Cs, Ts and Gs. Some mutations which are called variants are harmless. You can think of a spelling mistake or a difference in spelling that wouldnt change the word, right? So the American gray, which is G-R-A-Y versus the British grey, G-R-E-Y. If you saw that in a sentence, its gray. Its the color.

But then it could be a spelling mistake that completely blows up the function of a protein, and then in that case, somebody could have a terrible genetic disease or could have an extremely high risk of cancer, or a flu virus could now be resistant to a drug or something like that, or resistant to your immune response. Or, mutations could also be beneficial, right? This is what allows evolution. This is how flu viruses of all the bacteria evolve to become drug resistant or gain some new enzymatic function that it needs to survive.

Bloom: For instance, in the case of mutations in the human genome, we know that everybody has mutations relative to the average human. Some of those mutations will have really major effects, some of them wont. The very traditional way or the way that people have first tried to understand what those mutations do is to sequence the genomes of a group of people and then compare them. Maybe here are people who got cancer and here are people who didnt get cancer and now you look to see which mutations are in the group that got cancer versus the group that didnt, and youll try to hypothesize that the mutations that are enriched in the group that did get cancer are associated with causing cancer.

This is a really powerful approach, but it comes with a shortcoming which is that theres a lot of mutations, and it gets very expensive to look across very, very large groups of people. And so the idea of a technique like deep mutational scanning is that we could simply do an experiment where we test all of the mutations on their own and we wouldnt have to do these sort of complicated population level comparisons to get at the answer. Because when youre comparing two people in the population, they tend to be different in a lot of ways, and its not a very well-controlled comparison. Whereas you can set up something in the lab where you have a gene that does have this mutation and does not have this mutation, and you can really directly see what the effect of that mutation is. Really, people have been doing that sort of experiment for many decades now. Whats new about deep mutational scanning is the idea that you can do that experiment on a lot of mutations all at once.

Starita: And its called deep because we try to make every possible spelling mistake. So every possible change in the amino acid sequence or the nucleotide sequence, which is the A, C, Ts and Gs, across the entire gene or the sequence were looking at.

Bloom: Lets say we were to compare me and Lea to figure out why one of us had some disease and other ones didnt. We could compare our genomes and theres going to be a lot of differences between them, and were not really going to know what difference is responsible. We dont even really know if it would be a change in their genomes thats responsible. It could be a change in something about our environment. So the idea behind deep mutational scanning is we would just take one gene. So in the case of Lea, she studies a particular gene thats related to breast cancer, and we would just make all of the individual changes in that gene and test what they do one by one. And then subsequently if we were to see that a mutation has some effect, if we were to then observe that mutation when we sequenced someones genome, we would have some idea of what it does.

Starita: The deep mutational scanning, the deep part is making all possible changes. We have all of that information at hand in an Excel file somewhere in the lab that says that this mutation is likely to cause damage to the function of the protein or the activity of the protein that it encodes. Making all of the possible mutations. Thats where the deep comes from.

TB: How exactly are you doing this? Is it because of advances in computer processing or is it because of a change in approach that has enabled this increase in volume of the different mutations you can look at?

Bloom: I would say that theres a number of technologies that have improved, but the really key one is the idea that the whole experiment can be done all at once. The traditional, if you were to go back a few decades way of doing an experiment like this, would be take one tube and put, lets say the normal or un-mutated gene variant in that, and then have another tube which has the mutant that you care about, and have somehow do an experiment on each of those two tubes and that works well.

But you can imagine if you had 10,000 tubes, it might start to become a little bit more difficult. And so the idea is that really the same way that people have gotten very good at sequencing all of these genomes, you can also use to make all of these measurements at once. The idea is you would now put all of different mutants together in the same tube and you would somehow set up the experiment, and this is really the crucial part of the whole thing, set up the experiment such that the cell or the virus or whatever youre looking at, how well it can grow in that tube depends on the effect of that mutation. And then you can just use the sequencing to read out how the frequencies of all of these mutations have changed. You would see that a good mutation that lets say helped the cell grow better would be more representative in the tube at the end, and a bad mutation would be less representative in the tube. And by doing this you could in principle group together tens of thousands or even hundreds of thousands or millions of mutations all at once and read it all out in one experiment.

Starita: This has been enabled by that same revolution that has given us the thousand dollar genome. These DNA sequencers that were now using, not really to sequence human genomes, but were using them as very expensive counting machines. So, were identifying the mutation and were counting it. Thats basically what were using the sequencers for. Instead of sequencing human genomes, were using them as a tool to count all of these different pieces of DNA that are in these cells.

TB: At what stage of development is deep mutational scanning?

Starita: It started about 10 years ago. The first couple of papers came out in 2009 and 2010 actually from the Genome Sciences department at University of Washington. Those started with short sequences and very simplified experiments, and we have been working over the years to build mutational scanning into better and more accurate model systems, but that are increasing the complexity of these experiments. And so weve gone from almost, Hey, thats a cute experiment you guys did, to doing impactful work that people are using in clinical genetics and things like that.

TB: When youre at a holiday party and somebody asks you what you do and then they get really into it and they ask you, Wait, what are the implications of not only personalized medicine but this deep mutational scanning? Whats this going to mean for my life?

Starita: Right now it hasnt been systematically used in the clinic, but well get phone calls from UW pathology that says, Hey, I have a patient that has this variant. We found the sequence variant and this patient has this phenotype. What does this mutation look like in your assay? And were like, Well, it looks like its damaging. And then they put all of that information together and they can actually go back to that patient and say, You are at high risk of cancer. Were going to take medical action. That has happened multiple times. Were working right now to try to figure out how to use the information that we are creating. So these maps of the effect of mutations on these very important proteins and how to systematically use them as evidence for or against their pathogenicity. Right now for a decent percentage of these people who are telling them, Well, youve got changes but we dont know what they do. We want those tests to be more informative. So you go, you get the test, they say, That is a bad one. That ones fine. That mutation is good. That ones OK. That one, though. That ones going to cause you problems. We want more people to have more informative genetic testing because right now in a decent proportion of tests come back with an I have no idea, answer.

Bloom: You can also think about mutations that affect resistance to some sort of drug. For many, many types of drugs, these include drugs against viruses, drugs against cancers and so on, the viruses and the cancers can become resistant by giving mutations that allow them to escape from that drug. In many cases there are even multiple drugs out there and you might have options of which drug to administer, but you might not really know which one. Clinicians have sort of built up lore that this drug tends to work more often or you try this one and then you try this other one, but because how well the drug works is probably in general determined by either the genetic mutations in lets say the cancer or the person or the genetic mutations in the virus or pathogen, if you knew what the effects of those mutations were ahead of time, you could make much more intelligent decisions about which drugs to administer. And there really shouldnt be a drug that works only 50 percent of the time; youre probably just not giving it in the right condition 50 perfect of the time. Wed like to be able to pick the right drug for the right condition all the time.

TB: And thats what precision medicine is about.

Starita: Yes.

TB: Deep mutational scanning as a tool.

Starita: To inform precision medicine.

Bloom: These deep mutational scanning techniques were really developed by people like Jay Shendure and Stan Fields, and Lea and Doug Fowler to look at these questions of precision medicine from the perspective of changes in our human genomes affecting our susceptibility to diseases. I actually work on mutations in a different context, which has mutations in the viruses that infect us and make us sick. These viruses evolve quite rapidly. In the case of flu virus, youre supposed to get the flu vaccine every year. The reason why you have to get it every year is the virus is always changing and we have to make the vaccine keep up with the virus. The same thing is true with drugs against viruses like flu or HIV. Sometimes the viruses will be resistant, sometimes the drugs will work. These again have to do with the very rapid genetic changes that are happening in the virus. So, were trying to use deep mutational scanning to understand how these mutations to these viruses will affect their ability to, lets say, escape someones immunity or escape a drug that might be used to treat that person.

TB: How far along are you on that path?

Bloom: Were making progress. One of the key things weve found is that the same mutation of the virus might have a different impact for different people. So we found using these approaches that the ways that you mutate a virus will allow the virus sometimes to escape from one persons immunity much better than from another persons immunity. And so were really right now trying to map out the heterogeneity across different people. And hopefully that could be used to understand what makes some people susceptible to a very specific viral strain versus other people.

TB: And so then would your research extend into the mutations in human genes in addition to the changes in the virus?

Bloom: You could imagine eventually wanting to look at all of those combinations together, and we are very interested in this, but the immediate research were focusing on right now actually probably is not so much driven by the genetics of the humans. In the case of influenza virus, like I was saying, we found that if theres a virus that has some particular mutation, it might, lets say, allow it to escape from your immunity but not allow it to escape from the immunity of me or Lea. That doesnt seem to be driven as much we think by our genetics, but rather our exposure histories. So in the case of influenza, were not born with any immunity to influenza virus. We build up that immunity over the course of our lifetime because we either get infected with flu or we get vaccinated with flu and then our body makes an immune response, which includes antibodies which block the virus. Each of us have our own personal history, not genetic history, but life history of which vaccinations and which infections weve gotten. And so, that will shape how our immune response sees the virus. As a result, we think that that doesnt really have so much of a genetic component as a historical component.

TB: Just going with the flu example, could this result in a future big picture where I go in to get my flu vaccine and its different than the one the next person might go in to get?

Bloom: What we would most like to do is use this knowledge to just design a vaccine that works for everybody. So that would just be the same vaccine that everyone could get. But its a very interesting I think at this point I would say its almost in the thought experiment stage to think about this. When you think of something like cancer, like Lea was saying, you can use these tools to understand when people have mutations that might make them at risk for a cancer, but thats actually often a very hard thing to intervene for, right? Its not so easy to prevent someone from getting cancer even if you know theyre at risk. But obviously if people are able to do that, theyre interested in spending a lot of money to do it, because cancer is a very severe thing and you often have a very long window to treat it.

Something like a flu virus is very much at the other end. If I had the omniscient capability to tell you that three days from now youre going to get infected with flu and youre going to get really sick, we could prevent that. We have the technology basically right now to prevent that, if its nothing else than just telling you to put on a bunch of Purell and dont leave your bedroom. But theres also actually some pretty good interventions including prophylactics to flu that work quite well. But the key thing is, right now we think of everyone in the world as being at risk all the time and you cant be treating everybody in the world all the time against flu. Theres just too many people and the risk that any person

Starita: Not that much Tamiflu on the market.

Bloom: Not that much, and the risk of it So I think to the extent that we could really identify whos at the most risk in any given year, that might allow us to use these interventions in a more targeted way. Thats the idea.

TB: And how does deep mutational scanning lead to that potentially?

Bloom: Yeah. So the idea, and at this point, this is really in the research phase, but the idea is if we could identify that say certain people or certain segments of the population, that because of the way their immunity, lets say, is working makes them very susceptible to the viral mutant that happens to have arisen in this particular year, we could then somehow either suggest that theyre more at risk or, as you suggested, design a vaccine thats specifically tailored to work for them. So thats the idea. I should make clear that that is not anywhere close to anybody even thinking of putting it into economic practice at this point because even the concepts behind it are really quite new. But I do think that theres a lot of potential if we think of these infectious diseases not so much as an act of God, where you just happened to someone sneezed on you as youre walking down the street, but actually a complex interaction between the mutations in the virus and your own either genetics or immune system, we can start to identify who might be more at risk for certain things in certain years, and that would at least open the door to using a lot of interventions we already have.

Starita: The first year was three years ago, and some very enthusiastic graduate students started it. Basically, it was almost like a giant lab meeting where everybody who is interested in this field came. Somebody tweeted it out and then all of a sudden people from UCSF were there and were like, What the heck? It was great and we all talked about the technology and how we were using it. The next year, the Brotman Baty Institute came in and were like, OK, well, maybe if we use some of this gift to support this, we can have a bigger meeting. And then it was 200 people in a big auditorium and that was great. And now this year, its a two-day symposium and workshop, and its also co-sponsored by a grant from the National Human Genome Research Institute. But now weve got hundreds of people, so about 200 people again, but now flying in from all over the world. Weve got invited speakers, and the workshop, which is Tuesday, is a more practical, If youre interested in this, how do you actually do these experiments?

TB: Whats driving the interest in deep mutational scanning?

Bloom: We are starting to have so much genetic information about really everything. It used to be, going back a couple of decades, a big deal to determine even the sequence of a single flu virus. It was totally unthinkable to determine the sequence of a human genome, right? If you dont know what mutations are there, you dont really care that much what they do. Now we can determine the sequence of tens of thousands of flu viruses. I mean, this is happening all the time, and we can determine the sequence of thousands, even tens of thousands of human genomes. So now it becomes, as Lea said, really important to go from just getting these sequences to understanding what the mutations that you observe in these sequences actually will mean for human health.

See this site for more on the Brotman Baty Institute for Precision Medicine and the Deep Mutational Scanning Symposium and Workshop, Jan. 13 and 14 in Seattle. The symposium is free to attend if youre in the Seattle area, and it will also be livestreamed, with archived video available afterward.

Read the rest here:
Scientists pursue new genetic insights for health: Inside the world of deep mutational scanning - GeekWire

Targeting the BFPs of the CNS, Biogen licenses map of genetic neighborhoods in the brain – Endpoints News

Searching for new methods of attacking serious central nervous system diseases, Biogen has signed a deal that could be run into the hundreds of millions of dollars to essentially license a transcriptional map of the brain and scan it for new drug targets.

The partnership, worth $15 million upfront and far more in milestones, is with a new bioinformatics startup called CAMP4 Therapeutics. Founded in 2018 year by the Whitehead Institutes Richard Young and Harvard Medical Schools Leonard Zon, CAMP4 takes genes considered affiliated with a disease and maps out the various ways cells express those genes and turn them on or off. They then take that map and in the biological equivalent of stretching a war map across a table in a bunker mark up all the different methods of attack.

The more we know about a gene, it doesnt mean we can drug that gene, CEO Josh Mandel-Brehm, who worked at Biogen before joining CAMP4, told Endpoints News. Many genes are not quote-un-quote druggable, so then we have an interesting problem: I think I understand the genetics of the disease, but how do I drug it? And thats where our map solves for this problem.

Alongside the $15 million upfront payment, CAMP4 will be eligible for up to $96 million in milestones for each of the initial targets it supplies, and up to $173 million for each subsequent one.

Biogen is not disclosing what genes or diseases they will target, but the collaboration will focus on microglial cells. These macrophages are found in the central nervous system and have long been considered a key factor in neurodegenerative diseases such as Alzheimers and Parkinsons.

Biogen will bring CAMP4 the genes it believes are central to diseases in the central nervous system, and CAMP4 will inform them all the ways the gene is being expressed and where Biogen might go about turning up or down the expression.

So you say hey I want to move this particular gene for this disease, how should I do that? I want to change the expression of it,' Mandel-Brehm said, describing how they work with partners. Well show you the different nodes, if you will: hey you can drug this, you can drug this, you can drug this. Its modality agnostic.

CAMP4, founded out of Polaris Partners, is one of a couple of new biotechs that build on a discovery Young had back in 2015. The longtime transcriptional biologist published work showing that cells modify gene expression using a series of insulated neighborhoods, 3-D loops of DNA that control gene expression within them. CAMP4 maps those (along with other aspects of the transcriptome). Flagship Pioneerings new Omega Therapeuticsalso tries to drug them.

Since launching in 2018, CAMP4 has done extensive work on mapping genes for liver diseases, including NASH, as part of an in-house development program. Theyve also partnered with synthetic RNAi company Alnylam and are working to expand their maps of cells in the brain, heart, muscles, immune system, blood and kidneys, which they could then license out or use to develop drugs in-house.

The way I think about the diseases were going after is BFP: Big Fucking Problems,Mandel-Brehm said, citing NASH and other diseases that lack effective treatments. And Its well-validated and understood: If youre drugging something thats tied to the gene, youre much more likely to be successful.

Read more here:
Targeting the BFPs of the CNS, Biogen licenses map of genetic neighborhoods in the brain - Endpoints News

Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to serological memory – Science

INTRODUCTION

The prevalence and impact of type 1 hypersensitivity reactions, including allergic asthma, atopic dermatitis, life-threatening anaphylaxis, some food/insect/drug allergies, and allergic rhinitis, continue to rapidly increase worldwide (1). Immunoglobulin E (IgE) is a key player in the development and progression of such diseases (2). Although allergen-induced cross-linking of allergen-specific IgE bound to Fc receptors on effector cells is a trigger for the acute allergic response, the source of IgE serological memory remains elusive.

IgE is the isotype with the lowest abundance and shortest half-life in serum, lasting 2 to 3 days in humans (3) and ~12 hours in mice (4). IgE-producing cells are rarely detected in circulation (5), which presents a substantial challenge for the identification and characterization of these cells. In addition, traditional staining techniques have largely been unreliable in distinguishing IgE classswitched, membrane IgE+ cells from cells that bind soluble IgE via the high-affinity IgE receptor, FcRI, or the low-affinity IgE receptor, FcRII (CD23). Previous studies have tried to overcome this challenge by stripping IgE from its receptors using low pH (acid wash), by blocking extracellular IgE before intracellular staining, or by using different membrane IgE reporter systems (611). Using such detection systems, IgE+ B cells have been shown to exit germinal centers (GCs) prematurely and undergo early differentiation to short-lived plasma cells (PCs) during 4-hydroxy-3-nitrophenylacetylkeyhole limpet hemocyanin (NP-KLH) immunization or helminth infection (8, 9, 11). In contrast to IgG1+ cells, short-lived IgE+ PCs have been shown to express higher membrane IgE compared with IgE+ B cells (9). Signaling through the IgE B cell receptor (BCR) has been shown to induce apoptosis in IgE-switched cells, limiting their life span in secondary lymphoid organs (7). In addition, during NP-KLH immunization, IgE+ PCs were undetectable in the bone marrow (BM) (9). Collectively, these data argue against the presence of IgE cellular or serological memory in some murine models.

In contrast, several clinical observations suggest the presence of IgE serological memory in atopic patients. For example, persistent production of serum IgE is observed in allergic patients in the absence of allergen reexposure (1214). The inadvertent transfer of allergies and detection of allergen-specific IgE after BM transplant from allergic donors also argue for the presence of IgE+ BMPCs in atopic individuals (15, 16). In addition, treatments that ablate IgE+ B cells and short-lived plasmablasts (e.g., membrane IgE depleting antibody) or prevent class switching to IgE [e.g., interleukin-4 (IL-4)/IL-13 blocking antibodies] reduce serum IgE but are unable to bring serum IgE back to baseline (1720), indicating the presence of an IgE serological memory source that cannot be efficiently targeted with currently available therapies (20).

The mouse studies using reporter systems cited above relied on antigens delivered by injection with potent adjuvants, and none mimicked natural allergen exposure routes. These circumstances contrast with those required for the emergence and maintenance of allergic diseases, namely, continuous or intermittent exposure to allergen, often delivered by inhalation (e.g., mold, pollen, dust mite, or animal dander). In this study, we used murine models of short-term (4 weeks) and chronic (15 weeks) allergen exposure to study the IgE response in a model that mimics natural routes of environmental allergen exposure and identify the source of allergen-specific IgE memory. Using dual reporter mice that track IgE-producing cells (membrane IgEVenus) and PCs (Blimp-1mCherry), we show that 4-week allergen exposure results in the generation of IgE+ B cells and plasmablasts/PCs that mainly reside in secondary lymphoid organs and do not produce allergen-specific IgE that is able to mediate an anaphylaxis response. In contrast, chronic exposure to house dust mite (HDM) extract results in IgE+ PCs that primarily arise from sequential class switching of IgG1+ B cells, show similar CXCR4 expression to IgG1+ PCs, and gradually accumulate in the BM. We also demonstrate that, in contrast to IgE produced from secondary lymphoid organs during short-term allergen exposure, allergen-specific IgE that is produced from BMPCs, in both humans and mice, can cause mast cell degranulation and initiate anaphylaxis.

It is well established that the BM provides a niche that allows PCs to survive for long periods of time and that antibody derived from these cells confers IgG serological memory in the absence of nave or memory B cells (21), for example, the protective response to viral infection in vaccinated individuals. In contrast, the existence of long-lived IgE+ PCs in allergy models and their contribution for IgE serological memory has been controversial in previous literature. Some studies in mice have failed to detect IgE+ PCs in the BM, and in humans, the presence of IgE+ PCs has yet to be convincingly addressed [reviewed in (5)]

To explore this question in mice, we relied on a mouse model that recapitulates features of continual, chronic allergen exposure in humans. Repeated HDM exposure has been shown to elicit several hallmarks of allergic asthma, including airway hyperresponsiveness, lung remodeling, increase in serum IgE and IgG1, and induction of type 2 cytokines and chemokines (22, 23). Accordingly, we exposed mice to HDM intranasally, three times per week either for 4 weeks (4 weeks HDM), to induce type 2 allergic inflammation, or for 15 weeks (15 weeks HDM), to induce mixed type 2 and type 1 inflammation (22, 23).

Overall, PC frequency in the BM increased significantly after 15 weeks of HDM exposure compared with mice exposed to saline (Fig. 1A). This PC accumulation was not observed in mice exposed to HDM for 4 weeks, suggesting that longer exposure to allergens is needed to expand PCs within the BM compartment (Fig. 1A). As an initial step to characterize BMPCs, we purified CD138+ PCs, isolated RNA, performed RNA sequencing, and looked for the presence of IgE transcripts. IgE transcripts were detected within sorted BMPCs from mice exposed to HDM for 15 weeks, suggesting that IgE+ PCs are present in the BM of mice chronically exposed to allergen (Fig. 1B). Consistent with a PC phenotype, Ig genes were among the most abundantly expressed genes in CD138+ cells purified from 15-week HDM BM (Fig. 1B).

(A) Representative plots of BMPCs in mice exposed to either saline or HDM for 4 or 15 weeks (wks). Numbers on each plot indicate the percentage of CD138+ PCs within a dump population (left) and quantification as the percentage of live cells (right). (B) Ig heavy-chain RNA expression in sorted CD138+ BMPCs exposed to HDM for 15 weeks. (C) Quantification of total Blimp-1mCherry+ PCs in the BM of saline or HDM-exposed mice (percentage of live cells). (D) Comparison of serum IgE in WT and IgEVenus homozygous/Blimp-1mCherry heterozygous double reporter mice exposed to saline or HDM for 15 weeks. (E) Membrane IgEVenus/Blimp-1mCherry single and double reporter mice were intranasally exposed to either saline or HDM for 4 and 15 weeks. Representative dot plots of IgEVenus+ cells within dump/IgD population in the BM (left) (refer to fig. S2D for gating). Quantification (shown as the percentage of live cells) of IgEVenus+ single reporters (center graph) and IgEVenus/Blimp-1mCherry double reporters (right graph). FSC, forward scatter height. (F) The frequency of PCs (Blimp-1mCherry+) and B cells (B220+ Blimp-1mCherry) was analyzed within the IgEVenus+ gate in the BM of 15-week HDM-exposed double reporter mice. (G) CD138 expression assessed within the IgEVenus/Blimp-1mCherry IgE PC population in the BM (left) and quantified (right). (H) Representative dot plots of IgEVenus+ cells within dump/IgD population in the spleen of saline- or HDM-exposed mice (left) and (I) the distribution of IgE PCs (Blimp-1mCherry+B220) and IgE B cells/plasmablasts (B220+ Blimp-1mCherry). *P 0.05, **P 0.01, ***P 0.001, ****P 0.0001.

CD138 is not unique to BMPCs because it is expressed on epithelial cells, macrophages, dendritic cells [data assembled by the ImmGen consortium (24)], and pre-B and immature B cells in the BM (25). Thus, use of CD138 as a PC marker requires the use of a dump gate (fig. S1A). We looked for potential surface markers that are highly up-regulated in BMPCs. Ly6D, which has been previously identified during early B cell development and late PC differentiation (26, 27), was highly expressed in BMPCs during chronic allergen exposure (fig. S1B). Surface expression of Ly6D was validated on BMPCs, and when combined with CD138, these two markers revealed a distinct population of PCs (fig. S1C). Other receptors that were highly transcribed in our sorted population included known markers of a PC phenotype, including CAMPATH-1 antigen (CD52), major histocompatibility complex II (MHC II) invariant chain (CD74), and B cell maturation antigen (BCMA; TNFRSF17) (fig. S1B).

Our results demonstrated that there are challenges in identifying IgE-producing cells. We have shown that CD138 is not exclusive to BMPCs and have identified additional markers for PCs that could be useful. Given the challenges in tracking IgE-producing cells and the limited available information about whether IgE+ PCs express comparable markers as other isotypes, we generated a dual reporter mouse strain to thoroughly track and characterize the source of IgE production in the context of chronic allergen exposure.

To reliably detect IgE PCs in mice, we generated a dual reporter system that combines two different previously reported strategies to track IgE-producing cells and total PCs (9, 28). To track IgE-switched cells, we generated IgEVenus reporter mice in which the yellow fluorescent protein derivative, Venus, was inserted downstream of the final membrane IgE exon (M2) linked by a viral P2A peptide to enable simultaneous reporter expression with membrane IgE (fig. S2A, top). To monitor PCs, we generated Blimp-1mCherry reporter mice in which the fluorescent reporter, mCherry, was inserted downstream of the PC transcription factor Blimp-1 (Prdm1) (fig. S2A, bottom).

To validate that the Venus reporter system can track IgE-switched cells, we purified splenic B cells from IgEVenus mice and treated them with CD40 ligand (CD40L) and IL-4, which together induce class switching of nave B cells to IgE+ and IgG1+ cells. After 4 days in culture, IgE classswitched Venus+ cells were readily detectable, indicating that the reporter is functional (fig. S2B, top). A similar strategy of in vitro class switching was used to validate mCherry expression in Blimp-1mCherry mice (fig. S2B, bottom). After 4 days in culture, Blimp-1 was up-regulated in ~60% of IgE+ cells and ~10% of IgG1+ cells (fig. S2C). This confirms a previous finding that, relative to IgG1, IgE BCR signaling promotes Blimp-1 expression and bias toward PC differentiation in IgE+ B cells, independent of antigen (9).

To further characterize these mice and confirm our results from sorted CD138+ PCs (fig. S1), we exposed Blimp-1mCherry mice to HDM for 4 or 15 weeks and observed mCherry+ PC accumulation in the BM after 15 weeks of HDM exposure (Fig. 1C and fig. S2D). Consistent with a mature PC phenotype, B cellspecific transcription factors and surface receptors were down-regulated in BMPCs, including Pax5, Bcl6, Cd19, and Fcer2a (CD23), whereas PC transcription factors, such as Irf4 and Prdm1 (Blimp-1), were expressed (fig. S2E).

Having validated these two reporter mouse lines, we combined them to generate mIgEVenus/Blimp-1mCherry double reporter mice, where IgE+ PCs would be marked as Venus+/mCherry+. These three reporter lines (membrane IgEVenus single reporter, Blimp-1mCherry single reporter, and the double reporter mice) were used in the subsequent experiments.

To track IgE+ PCs during chronic allergic inflammation, we treated mIgEVenus/Blimp-1mCherry single and double reporter mice with HDM for 4 or 15 weeks. Serum IgE levels in dual reporter mice exposed to chronic HDM were comparable with serum IgE induced in wild-type (WT) mice by the same HDM exposure (Fig. 1D), confirming that the IgE response induced in the dual reporter mice is comparable with that of WT mice. IgE-Venus+ cells accumulated in the BM after 15 weeks of repeated HDM exposure (Fig. 1E), and almost all of the IgE-Venus+ cells expressed Blimp-1 and did not express the B cell marker B220 (Fig. 1F), indicating that these cells were mature BMPCs. We noticed that about half of B220 Blimp-1+ IgE+ BMPCs did not express CD138 (Fig. 1G), which has been conventionally used as a marker to identify IgE+ PCs in previous studies. These results further support the need for additional surface markers to identify IgE+ BMPCs and suggest that IgE+ BMPCs quantified from the CD138-gated cells may be an underestimation of the actual frequency, as also evidenced by IgE reads per kilobase, per million mapped reads (RPKM) values from the BM of reporter mice (fig. S2F, compare with Fig. 1B).

To examine the kinetics of IgE class switching and differentiation into PCs in secondary lymphoid organs, we measured Venus expression in the spleen of HDM-exposed mice and found that mIgEVenus+ cells could be detected in spleen during short-term (4 weeks) HDM exposure (Fig. 1H). Similar to previous reports with NP-KLH immunization (9), we detected two distinct Venus+ populations in spleen, corresponding to IgE+ B cells/early plasmablasts (Venus+ B220+) and IgE+ PCs (Venus+ Blimp-1+B220) (Fig. 1I). Together, these data indicate that short-term (4 weeks) allergen exposure to HDM is sufficient to induce IgE-producing cells in secondary lymphoid organs but not for accumulation in the BM.

To determine whether IgE+ PCs that migrate to the BM during chronic allergic inflammation contribute to IgE serological memory, mIgEVenus reporter mice were exposed to HDM for either 4 or 15 weeks and rested (in the absence of allergen exposure) for an additional 9 weeks (Fig. 2A). Because the half-life of IgE in serum is ~12 hours in mice (4, 29), IgE+ plasmablasts are short-lived in secondary lymphoid organs (30, 31), and there is no allergen exposure that would drive de novo IgE production during rest, we hypothesized that any IgE detected after 9 weeks of rest comes from long-lived IgE+ PCs.

(A) Experimental setup for HDM exposure and rest. (B) Serum IgE ELISA in mice exposed to HDM for four weeks or (C) 15 weeks of HDM, with or without subsequent 9 weeks of rest. ns, not significant. (D) Representative plots of Venus+ cells in the BM after saline or HDM exposure 9 weeks of rest (left) and quantification of membrane IgEVenus+ cells in the BM (right). (E) CXCR4 expression on membrane IgEVenus+ PCs (B220 Venus+) compared with IgG1 PCs (IgG1+, B220) in mice treated with chronic HDM rest. Experiments were performed using IgEVenus heterozygous and Blimp-1mCherry heterozygous mice. MFI, mean fluorescence intensity. *P 0.05, **P 0.01, ***P 0.001, ****P 0.0001.

The level of serum IgE increased in mIgEVenus reporter mice exposed to HDM for 4 weeks, and these levels decreased after the 9-week rest period, approaching but not reaching levels detected in mice exposed to saline alone (Fig. 2B). This suggests that most of the IgE produced after 4 weeks of HDM exposure comes from short-lived PCs and requires allergen reexposure to drive de novo class switching to IgE. Mice treated with HDM for 15 weeks displayed higher serum IgE levels as compared with 4-week HDM mice, and when rested for 9 weeks, they maintained significantly higher serum IgE levels than mice exposed to saline alone (Fig. 2C). These results demonstrate that after chronic HDM exposure, the contribution of long-lived IgE+ PCs to the serum IgE response is greater than it is after short-term HDM exposure.

The IgEVenus+ BMPCs generated after 15 weeks of HDM exposure were maintained after 9 weeks of rest (Fig. 2D), suggesting that this population of cells contributes to the maintenance of IgE levels. This experiment was repeated in nonreporter mice, and IgE+ PCs were also detected in the BM by intracellular IgE staining after 15 weeks of HDM exposure and 9 weeks of rest, thus confirming the findings from reporter mice (fig. S3, A and B).

Although CXCR4 expression has been previously linked to migration and retention of BMPCs (32), IgE plasmablasts have been reported to lack CXCR4 expression, possibly explaining their inability to populate the BM (33). In contrast to these observations, IgE+ BMPCs generated during chronic allergen exposure expressed CXCR4 at levels comparable to IgG1+ PCs, and CXCR4 expression was maintained after the rest period (Fig. 2E). Together, these findings indicate that after continual chronic allergen exposure, IgE PCs accumulate in the BM, express CXCR4 at levels similar to those of IgG1+ BMPCs, and can be retained within the BM during a rest phase.

To further define whether these cells persist in the BM beyond the 9-week rest period and continue secreting IgE, we tracked serum IgE levels in mice exposed to HDM for 4 or 15 weeks and subsequently rested for ~6 to 7 months (29 weeks) (Fig. 3A and fig. S3C). In the 4-week HDM exposure model, the low level of serum IgE that we noted after 9 weeks of rest (Fig. 2B) plateaued and was maintained even after 23 weeks in the absence of allergen exposure (fig. S3C), suggesting limited but detectable IgE production that is driven by long-lived IgE+ PCs even after short-term allergen exposure. In the 15-week HDM-exposed mice, we observed that IgE levels slightly decline in the initial weeks of rest, and these levels also plateau after ~14 weeks and remain constant through the last time point assayed (29 weeks). These results suggest that, in the initial phase of rest, because short-lived IgE-producing cells disappear and de novo switching of B cells to IgE dissipates, a selected population of long-lived IgE-producing cells persists (Fig. 3A). The level at which the serum IgE plateaus is higher in mice that were exposed to HDM for 15 weeks relative to those exposed for 4 weeks, consistent with a progressive accumulation of long-lived IgE-producing cells over time.

(A) Serum IgE ELISA in mice exposed to HDM for 15 weeks and rested for 29 weeks. (B) Experimental setup for HDM exposure and rest anti-CD20 and IgG2a isotype (Iso) control monoclonal antibody (mAb) treatments. (C) Circulating B cell frequency before antibody treatment (left graph) and 7 days after antibody treatment (right graph) in mice exposed to HDM for 15 weeks and treated with anti-CD20 or IgG2a control monoclonal antibody. (D) Serum IgE levels at various time points over the course of a 32-week (8-month) rest period after 15 weeks of HDM exposure. (E) Representative plots of Venus+ cells in the BM after HDM exposure and 32-week rest anti-CD20 or IgG2a control monoclonal antibody treatment (top left) or intracellular IgE+ cells in the BM (bottom left) and quantification of membrane IgEVenus+ cells in the BM (top right) or intracellular IgE+ cells in the BM (bottom right). (F) Intracellular IgE staining within BM Venus+ cells. ****P 0.0001.

To further characterize the persistence of these IgE PCs, we exposed double reporter mice to HDM for 15 weeks, then treated mice with a single dose of an anti-CD20 antibody or an isotype control antibody, and rested them for an additional 32 weeks (8 months) while bleeding them every 3 to 5 weeks to track serum IgE levels. Anti-CD20, but not isotype control treatment, led to B cell depletion, as confirmed by flow cytometry analysis of circulating B cells 1 week after antibody administration (Fig. 3C). However, because CD20 is not expressed on PCs, anti-CD20 should not affect PCs that are already established. Anti-CD20 treatment had negligible effect on serum IgE levels relative to untreated or isotype controltreated mice (Fig. 3D). This result suggests that at the end of the 15-week HDM treatment, the majority of IgE production comes from PCs and not from B cells and that the reduction observed in the initial weeks of rest is likely due to the loss of preexisting short-lived PCs, whereas the persistent production of IgE in the later time points is driven by long-lived PCs. Consistent with these findings, IgE PCs were present in the BM at comparable frequencies in anti-CD20treated mice as compared with the control groups at the end of the 32-week rest period, demonstrating that, once established, this long-lived IgE population persists in the BM for a prolonged time (Fig. 3E and fig. S3D). Although anti-CD20mediated depletion of tissue-resident GC B cells has been reported to be inefficient, recirculating B cells and memory B cells can be eliminated using this approach (34). In addition, at the end of the 32-week rest, no increase in IgE+ PCs was detected in the spleens of anti-CD20treated mice relative to saline mice (fig. S4A), and GC B cells represented a comparable fraction of the B cell pool as compared with saline mice (fig. S4B), indicating that, at the time of harvest, there was no ongoing de novo production of IgE PCs in the spleens of anti-CD20treated mice. We detected IgE+ PCs in the lungs of these mice, suggesting that mucosal sites of allergen exposure can potentially act as additional reservoirs of long-lived IgE+ PCs (fig. S4, C to E).

The findings discussed above demonstrate that IgE+ BMPCs arise in significant numbers after chronic HDM exposure, and differential expression of CXCR4 on these cells relative to IgE+ plasmablasts suggests qualitative differences between IgE-producing cells generated during short allergen exposure relative to the IgE-producing cells that accumulate in the BM during chronic allergen exposure. To address potential mechanisms that might contribute to these differences, we focused on a unique feature of IgE+ B cells, namely, that they can either arise via a direct class switching pathway from IgM+ B cells or from sequential class switching of IgG1+ B cells (11).

To directly quantify the frequency of IgE-producing cells that were generated by direct versus sequential class switching during short versus chronic allergen exposure, we used a previously described strategy for measuring IgG1 switch junction remnants (S1 switch region sequences) within IgE-switched cells (35). Accordingly, DNA was amplified from pooled spleen of mIgEVenus mice exposed to HDM for 4 weeks or from BM of mice exposed to HDM for 15 weeks using primers for IgM switch region (S) to IgE switch region (S) (Fig. 4A). Because the DNA break during class switch recombination occurs at different sites, the first polymerase chain reaction (PCR) leads to multiple products of different sizes (Fig. 4A). The PCR product from both samples was then cloned, and individual colonies were sequenced (Fig. 4A and table S1). Inserts amplified from S and S PCR were examined for the presence of switch 1 remnant sequence by performing an alignment to the 49base pair (bp) repeat sequence found in IgG1 switch regions (36). In the spleen of mice exposed to HDM for 4 weeks, 12 of the 78 clones (15.3%) contained S1 remnant sequences (Fig. 4A and table S1). In contrast, in the BM of mice exposed to HDM for 15 weeks, 53 of 74 IgE switch region colonies screened (71.6%) contained S1 remnant sequences, suggesting that most of the IgE+ PCs detected in the BM during chronic HDM exposure were generated via sequential class switching from IgG1+ cells. To confirm these observations from the alignment data, we amplified individual colonies using a second primer set specific to S1 and S (Fig. 4B). S1 to S PCR would amplify 1 product/s depending on the length of S1 remnant left within the IgE switch region (Fig. 4B, representative gel). Using this PCR strategy, we confirmed the presence of S1 remnant sequences in ~75% of IgE switch region colonies screened, consistent with the alignment data.

(A) Quantification of the percentage of sequential class switching (presence of IgG1 remnants) within IgE-switched cells in the spleen of mice exposed to HDM for 4 weeks or the BM of mice exposed to HDM for 15 weeks (refer to table S1). VDJ, variable-diversity-joining. (B) The presence of S1 remnant sequence within IgE clones in the BM of 15-week HDM-exposed mice was confirmed by PCR using primers specific to S1 repeat region and S. Image shows representative gel from one experiment. The presence of 1 band indicates that the IgE-switched clone contains IgG1 remnants and was derived from sequential class switching of an IgG1+ cell.

It has previously been shown that during antigen-independent IgE class switching or a single immunization with NP-KLH, IgE+ plasmablasts undergo limited GC reaction and primarily arise from direct class switching pathway (11), similar to what we see with 4 weeks of HDM exposure in spleen. We show here that during chronic allergen exposure, IgE+ PCs that migrate to the BM predominantly arise from sequential class switching of IgG1+ cells.

Previous studies have shown that IgE-switched B cells exit GCs prematurely and rapidly differentiate into PCs (9). As a consequence, somatic hypermutation and affinity maturation are blunted, resulting in lower-affinity antibody relative to IgGs that are retained in the GCs for extensive affinity maturation. It has therefore been proposed that the generation of a high-affinity IgE response necessitates an IgG intermediate that is capable of acquiring high affinity before IgE switching (11). Having defined that most of the IgE+ BMPCs in chronically allergen-exposed mice come from sequential class switching, we hypothesized that this developmental history might have an important impact on the specificity, affinity, or overall pathogenicity of the IgE produced by these cells.

To determine the functional relevance and specificity of IgE produced by BMPCs, we used a passive systemic anaphylaxis (PSA) model, where nave mice were sensitized systemically with serum from either 4- or 15-week HDM-exposed mice or serum from mice rested for 9 weeks after HDM exposure (Fig. 5A and fig. S5). Recipient mice were then challenged systemically with an intravenous injection of Der p 1, a dominant allergen in HDM extract (37), and temperature changes in the mice were measured as a readout of systemic anaphylaxis (38).

(A) Groups of nave mice received an intravenous (I.V.) injection of serum from mice that were exposed to saline, 4 weeks, or 15 weeks HDM rest allowing allergen-specific IgE to bind FcRI-expressing cells systemically. After 24 hours, basal core temperature measurements were taken for all mice, followed by intravenous challenge with Der p 1 allergen. Core temperature change relative to basal temperature is shown as a readout for systemic anaphylaxis. (B) Histamine levels in the plasma of mice 30 min after Der p 1 challenge. (C) PCA (mast cell degranulation) was assayed by intradermal (I.D.) injection of the same sera as (A) from saline- or HDM-exposed mice. After 24 hours, the mice were challenged intravenously with Der p 1 diluted in 0.5% Evans blue dye. Evans blue dye was extracted from ear tissue and measured spectrophotometrically. Plot shows Evans blue dye extravasation in the tissue quantified as nanograms of Evans blue per milligram of tissue as a measure of local mast cell degranulation. **P 0.01, ***P 0.001, ****P 0.0001.

Initially, mice were sensitized systemically with serum containing HDM-specific IgE that was diluted twofold (Fig. 5A and fig. S5B). Mice that were sensitized with serum from 4 weeks HDM, or 4 weeks HDM + 9 weeks rest, showed a minor temperature drop upon Der p 1 challenge (Fig. 5A, left graph, and fig. S5B, left graph), similar to control (saline) mice. In contrast, mice sensitized with serum from 15 weeks of HDM exposure had symptoms of severe systemic anaphylaxis (~6 to 8C drop in core temperature) measured after 30 min of Der p 1 challenge (Fig. 5A, right graph, and fig. S5B, left graph). Similarly, mice that received serum from 15 weeks HDM + 9 weeks rest induced a comparable drop in core body temperature to mice sensitized with serum from 15-week exposed/unrested mice (Fig. 5A and fig. S5B). In addition, plasma histamine levels were significantly increased in these mice 30 min after challenge (Fig. 5B), confirming an ongoing anaphylactic response.

To determine whether the increase in systemic anaphylaxis after 15 weeks of HDM exposure was due to higher IgE concentration (~3-fold higher IgE in 15 weeks HDM relative to 4 weeks HDM; fig. S5A), we normalized the total amount of IgE used to sensitize the mice to 500 ng across all sera that were injected. Consistent with the previous data, only serum derived from chronic HDM exposure (9 weeks rest) induced systemic anaphylaxis (fig. S5B, right graph). These data suggest qualitative changes to the IgE pool after chronic allergen exposure that enable IgE pathogenicity.

It has previously been shown that both IgE and IgG are capable of inducing systemic anaphylaxis in mice (39). Thus, to further confirm these qualitative differences between the IgE generated in short-term versus chronic HDM exposure, we used a model that is IgE and mast cell dependent, namely, the passive cutaneous anaphylaxis (PCA) mouse model. The PCA model assesses type 1 hypersensitivity and measures local IgE-mediated mast cell activationinduced vascular permeability in tissue (40). In these studies, mice were passively sensitized intradermally in the ear with sera normalized to 25 ng of IgE and subsequently challenged with an intravenous injection of Der p 1 diluted in Evans blue dye. Vascular permeability induced by mast cell degranulation was then monitored by Evans blue leakage into ear tissue. Consistent with the PSA results, significant mast cell degranulation could only be induced when mice ears were sensitized with serum from 15 weeks of HDM exposure (Fig. 4C, left graph) or 15 weeks HDM + rest (Fig. 5C, right graph). These findings demonstrate that, in contrast to short allergen exposure, IgE produced during chronic HDM exposure is allergen specific and can drive local and systemic anaphylaxis.

The presence of IgE BMPCs and their contribution to the progression of allergy in patients are currently not well understood (5). To characterize IgE PCs in human BM, we obtained BM aspirates along with matched serum samples from five allergic donors and two age-matched controls with no history of allergy. The allergen-specific IgE profile of the donors was determined by ImmunoCAP, an in vitro diagnostic assay that detects allergen-specific IgE in human samples, and showed that one donor was only allergic to cats; the second was allergic to cats, dogs, HDM, and mold; the third was allergic to cats, dogs, and mold; the fourth donor was only allergic to olive; and the fifth donor was allergic to olive, grass, and mold (fig. S6A). This test also confirmed that sera from the two nonallergic donors were not reactive to any allergens tested.

To reliably detect IgE-producing cells in human BM, we adopted a previously described method where, in addition to gating out irrelevant or contaminating cell types [T cells (CD3+), myeloid cells (CD11b+), basophils, and other FcR1-expressing cells (FcR1+ and CD123+)], surface IgE was saturated with an unlabeled anti-IgE antibody, followed by intracellular IgE staining with the same antibody clone that is fluorescently labeled (9). Using this staining method, intracellular IgE+ cells were detected in the BM of all allergic individuals but not in nonallergic controls (Fig. 6A).

(A) Intracellular IgE staining of BM mononuclear cells from nonallergic and allergic individuals. Plots show Dump CD27+ CD38+ BMPCs (gating strategy: fig. S6B). Quantification of IgE BMPCs shown as percentage of live (middle graph) and percentage of BMPCs (right graph). (B) Comparison of expression levels of surface proteins (MFI) in allergic and nonallergic BMPCs and nave B cells. (C) BM mononuclear cells from three cat-allergic and two nonallergic donors were cultured in stromal cellconditioned media for 8 days, and supernatants (sup) were collected. IgE and IgG levels in the supernatants were measured by ELISA. ND, not detectable. (D) Serum IgE and total IgG were measured by ELISA in the same donors. (E) ImmunoCAP scores for cat danderspecific IgE within cultured BM supernatants from allergic and nonallergic donors. **P 0.01.

We further confirmed the PC phenotype of these cells by staining the cells with several PC markers. Compared with nave B cells, human BMPCs expressed significantly higher levels of the defined PC markers BCMA (TNFRSF17), IL-6R, and CD27 on their surface (gating strategy in fig. S6B). In contrast, expression of IL-4R and surface IgG was down-regulated on BMPCs compared with IgG B cells. The expression of all of these surface markers was comparable between allergic and nonallergic individuals (Fig. 6B).

When cultured in vitro, IgE+ PCs from the BM of the three cat-allergic donors produced detectable levels of IgE (Fig. 6C). IgE secretion was detectable by enzyme-linked immune absorbent spot (ELISpot) after 24 hours in culture (fig. S6C). This time frame is insufficient for de novo PC differentiation, thus confirming a preexisting population in the BM that readily secretes IgE in culture. After 8 days in culture, the secreted IgE levels mirrored the donor-to-donor variability observed in the allergic donor sera (compare Fig. 6, C and D, left graphs), where cells from cat-allergic donor 2 produced the highest amount of IgE and cells from cat-allergic donor 1 produced the lowest. IgE was not detected in serum or BM supernatant of the two nonallergic donors, whereas total IgG levels were comparable across all donors (Fig. 6, C and D, right graphs), independent of allergy status. Moreover, ImmunoCAP scores of BM supernatants from the three allergic donors confirmed cat dander reactivity of the IgE produced by these BMPCs (Fig. 6E). These data demonstrate that IgE-secreting PCs are present in the BM of allergic patients in frequencies that correlate with their serum IgE levels.

One limitation to modeling the human IgE response in mice is that human IgE does not bind mouse FcRI, the high-affinity IgE receptor that mediates anaphylactic responses (41). To circumvent this species specificity issue, we generated FcRI humanized mice (Fcer1ahu/hu), in which the full mouse Fcer1a coding region was replaced with human FCER1A coding sequence (Fig. 7A). In contrast to previously generated transgenic mice (42), these knock-in mice replace the entire mouse Fcer1a gene with human FCER1A and preserve regulatory elements that control expression levels (and, thus, thresholds of stimulation that will trigger anaphylaxis). The surface expression of human FcRI in these mice was confirmed on splenic basophils (Fig. 7B). In vivo local mast celldriven anaphylaxis was also confirmed in these mice using the PCA model (Fig. 7C) in which groups of WT or Fcer1ahu/hu mice received an intradermal injection in the ear with a cocktail of two Fel d 1 [major cat allergen (43)]specific human IgE antibodies or an irrelevant IgG antibody (negative control) into the right and left ears, respectively (Fig. 7C). After 24 hours, the mice were challenged by intravenous injection of Fel d 1 diluted in Evans blue dye. Mast cell degranulation was observed in Fcer1ahu/hu mice, but not in WT mice (Fig. 7C), demonstrating functionality of the mice and IgE: FcRI engagement and activation. Similar results were obtained using the PSA model (fig. S7A), further confirming successful humanization of FcRI. To further confirm that the PCA response was driven by IgE in serum, we performed a PCA challenge sensitizing with human cat-allergic donor serum in WT (non-FcR1 humanized) mice, where human IgE would not be able to bind to mouse FcR1. No response was observed in WT mice when they were sensitized with the human sera, confirming that serum IgE is the driver of the PCA response in the FcR1 humanized mice (fig. S7B).

(A) Humanization strategy for the full coding sequence of FcRI. (B) Spleens were harvested from WT or Fcer1ahu/hu mice, and single cell suspensions were stained with antibodies for the basophil marker CD49b and either mouse (top plots) or human (bottom plots) FcR1. (C) PCA response of WT or Fcer1ahu/hu mice sensitized with an intradermal injection with a cocktail of two allergen-specific human IgE antibodies or an irrelevant IgG antibody (negative control). (D to G) Ears of FcRIahu/hu were sensitized by intradermal injection of sera from nonallergic or cat-allergic donors (D), BM supernatant from nonallergic or cat-allergic donors (E), sera from nonallergic or olive-allergic donors [(F), right graph], or BM supernatant from nonallergic or olive-allergic donors [(G), right graph]. Plots show Evans blue dye extravasation as nanograms of Evans blue per milligram of tissue. Left graphs on (F) and (G) show IgE levels in serum and BM supernatant in olive-allergic and nonallergic donors, respectively. *P 0.05, **P 0.01, ****P 0.0001.

Subsequently, serum from each of the three cat-allergic donors, as well as the two nonallergic controls, was individually used to sensitize ears of Fcer1ahu/hu mice in the PCA model. Upon challenge with Fel d 1, the ears that were sensitized with any of the three cat-allergic donor sera showed Evans blue dye extravasation (Fig. 7D), whereas no Evans blue extravasation was observed in the ears sensitized with either of the two nonallergic donor sera. Donor-to-donor variation was observed among the three donors, and the number of IgE+ BMPCs in the individual donors correlated with the levels of serum IgE and the magnitude of the PCA response (Figs. 6D and 7D). In particular, donor 2, which had the highest frequency of IgE cells in the BM (Fig. 6A), also showed the highest level of serum and BMPC-derived IgE (Fig. 6, C and D) and induced the greatest PCA response (Fig. 7D). This donor was also the most polyallergic, being allergic to cats, dogs, HDM, and mold.

To directly demonstrate that the IgE secreted by BMPCs in atopic patients is allergen specific, we performed a PCA assay using supernatant from in vitro cultures of the BM of cat-allergic donor 2 (Fig. 7E). Ears sensitized with supernatant from the allergic donor, and not the nonallergic control, showed robust mast cell degranulation (Fig. 7E). We further investigated whether IgE+ BMPCs from donors with different allergies besides cat also produced pathogenic IgE capable of inducing anaphylaxis. For this, we sensitized FcR1 humanized mice with serum from an olive-allergic patient and challenged the mice with Ole e1, the primary allergen in olive pollen (44). Comparable with the data obtained with cat-allergic sera, IgE contained in the serum of the olive-allergic donor was also capable of driving mast cell degranulation in response to Ole e1 (Fig. 7F). Moreover, we also cultured the BM from this patient, and the IgE contained in the supernatant from this culture was capable of sensitizing mice and driving anaphylaxis in response to Ole e1 (Fig. 7G). Together, these findings directly demonstrate that human IgE+ PCs reside in the BM of atopic patients and secrete allergen-specific IgE of sufficient affinity to initiate an anaphylactic response.

In this study, we used HDM allergen exposure to compare the features of IgE-producing cells during a short-term (4 weeks) and long-term (15 weeks) allergic response. We demonstrate that short-term HDM exposure results in the generation of IgE+ B cells and PCs that mainly reside in secondary lymphoid organs (spleen) and produce IgE that is unable to induce robust mast cell degranulation in response to allergen. In contrast, long-term exposure to HDM leads to the generation of IgE+ PCs that primarily arise via sequential class switching of IgG1+ cells, express CXCR4 at levels similar to those in IgG1+ PCs, populate the BM, provide serological memory to the allergen, and produce allergen-specific IgE that can drive local and systemic anaphylaxis. We find that IgE+ PCs also reside in the lung and persist after B cell depletion and 8 months of rest, indicating that this is an additional reservoir of long-lived IgE+ PCs contributing to serological memory. The kinetics with which IgE-producing cells arise and persist in the lung and other mucosal sites of allergen exposure warrants further investigation.

The presence and relevance of long-lived IgE+ BMPCs in maintaining allergic memory have been debated in recent studies. After Nippostrongylus brasiliensis infection or NP-KLH challenge, IgE+ PCs were detected in lymph nodes transiently, followed by a marked decline by day 17 after immunization (9). IgE+ PCs were undetectable in the BM at this time point, suggesting that IgE-switched cells predominantly differentiated into short-lived plasmablasts that mainly resided in secondary lymphoid organs (9). Their inability to reach the BM was attributed to their short half-life in secondary lymphoid organs, because NP-KLH challenge in E-Bcl2-22 transgenic mice, a system that extends the life span of short-lived PCs by overexpression of the antiapoptotic protein B cell lymphoma 2, led to a ~20- to 30-fold increase in the frequency of IgE+ PCs in lymph nodes and a subsequent detection of these cells in the BM (9). In other studies, signaling downstream of the IgE BCR, which involves the Syk-BLNK-Jnk-p38 signaling pathway, was shown to induce apoptosis in IgE-switched cells and was implicated in shortening their life span within secondary lymphoid organs (7, 31). It is speculated that the combination of these restrictions, together with low expression of chemokine receptors required for BM homing [e.g., CXCR4 (33)], limits the ability of IgE+ PCs to migrate to the BM and become long-lived PCs that maintain serological memory (9, 30, 31, 33). Other reports found that IgE-producing cells can be detected in the BM after primary and secondary N. brasiliensis infection (8, 10), but these cells were not thoroughly characterized and their longevity in the BM or contribution to IgE serological memory was not addressed. IgE+ PCs have also been detected in the BM after ovalbumin (OVA) or peanut immunization, albeit in low numbers, and although they suggested that these BMPCs are capable of contributing to long-term production of serum IgE, they also proposed that the most relevant source of IgE memory lies predominantly in IgG1 memory B cells that can sequentially switch to IgE upon rechallenge (8, 45). Earlier literature, in contrast, has highlighted the importance of IgE serological memory in allergy models. One report showed the presence of X-irradiationresistant IgE production after immunization with dinitrophenyl-KLH (DNP-KLH) or DNP-OVA (46). Persistent production of OVA-specific IgE after repeated low-dose inhalation of aerosolized OVA has also been reported, and this IgE was shown to be resistant to radiation and cytostatic drugs (14, 47).

It is challenging to compare different models that generate IgE+ PCs, because the amount of IgE+ PCs induced and the kinetics of IgE+ PC migration would likely vary with different allergens, routes of sensitization, and differences in the genetic background of the mice used. The discrepancy between the studies outlined above could also be explained by the primary readouts [e.g., enzyme-linked immunosorbent assay (ELISA) versus flow cytometry methods] used to quantify long-lived IgE+ PCs, as well as the length of the study to characterize these cells. In early studies that report persistent presence of long-lived IgE+ PCs in murine models, IgE production was tracked for ~1 year in serum of irradiated mice by ELISA (14), which would allow quantification of IgE secreted from the extremely low number of long-lived PCs that are present in different survival niches (e.g., BM, spleen, and lung). The number of IgE+ PCs with such models may not be sufficient to be detected by flow cytometry, which would explain how recent studies have not captured these cells using different IgE reporter systems. PCs can secrete ~108 Ig molecules per cell per hour (48), suggesting that even at extremely low numbers, long-lived PCs would be capable of maintaining life-long IgE serological memory.

Our data provide evidence to propose a unifying model of how allergy memory arises with allergen exposure (fig. S8). Consistent with previous reports using short-term immunizations, we found that 4 weeks of HDM exposure predominantly generated IgE+ plasmablasts that reside in secondary lymphoid organs, and when these mice were rested in the absence of allergen exposure, serum IgE was significantly reduced, likely indicating that the majority of this IgE comes from short-lived PCs. Nonetheless, we were still able to detect low levels of circulating serum IgE above basal levels in control mice, even after a 23-week rest phase. This suggests that a few long-lived IgE+ PCs are generated during short-term allergic inflammation, albeit at a much lower frequency compared with repeated/continuous exposure to the same allergen. In contrast, during a chronic response, the number of long-lived IgE+ PCs generated increases over time with persistent exposure to the allergen, allowing accumulation of these cells that become traceable in the BM. A recent report proposed that IgE+ PCs are preferentially displaced from the BM, with a half-life of ~8.5 weeks in the BM compared with ~33.5 weeks for IgG1+ PCs (45). However, this half-life calculation assumes a linear rate of decrease in both serum IgE and IgE+ BMPCs and does not reflect the fact that the decrease plateaus over time. We now report that after an initial decrease in serum IgE in the initial weeks of rest, the levels of serum IgE and of IgE+ BMPCs plateau and are preserved for at least 8 months and likely for the entire life span of the mouse. These data suggest that the initial decrease in serum IgE is due to the loss of short-lived IgE+ PCs, whereas some IgE+ clones are selected and retained in the BM indefinitely where they continue secreting IgE.

Although our data show a quantitative impact of long-term allergen exposure on the number of BMPCs that can sustain IgE production, we also find a remarkable change in the quality of the IgE generated during a chronic response. We find that, during chronic HDM exposure, IgE+ PCs primarily arise from sequential class switching of IgG1+ GC B cells and/or IgG1+ memory B cells. The consequences of this developmental history of IgE+ PCs are twofold: First, sequential switching may allow IgE+ PCs to retain some features of IgG1+ cells, such as surface markers or chemokine receptors (e.g., CXCR4), that increase their odds of homing to the BM. Consistent with this notion, previous reports have proposed that long-lived BMPCs are primarily derived from affinity-matured GC B cells (49). Second, unlike directly switched IgE+ B cells, which exit GCs prematurely and have limited capacity to undergo somatic hypermutation and increase affinity (8, 9, 11, 30, 50), IgG1+ B cells are capable of remaining in GCs and undergoing extensive affinity maturation, and memory IgG1+ B cells can further be recruited to the GC upon rechallenge to undergo additional rounds of affinity maturation (51). Sequential switching from IgG1 to IgE thus enables high-affinity IgG1+ clones to give rise to higher-affinity IgE+ clones (50), relative to those generated by direct switching from nave IgM+ B cells. We show that IgE only generated after chronic allergen exposure, but not after a short-term exposure, is capable of driving local or systemic anaphylaxis. This difference in the quality of the IgE was evident even when mice were sensitized with equal amount of serum IgE derived from short- or long-term allergenexposed mice (Fig. 5). We also find evidence of increased frequency of sequential class switching in the spleen of chronically HDM-exposed mice relative to mice with short-term HDM exposure. Together, these data suggest that during chronic allergen exposure, the pool of high-affinity IgG1+ intermediates that serve as precursors of IgE+ PCs gradually increases, thus enabling the production of higher-affinity IgE+ PCs and/or expansion of allergen-specific IgE+ clones. As a consequence, after chronic allergen exposure, most of IgE+ PCs come from IgG1+ intermediates, contrasting with models of antigen-independent B cell responses, short-term immunizations (one dose of NP-KLH), or parasite infections, where most of the IgE-producing cells are generated via direct switching, undergo limited rounds of affinity maturation, and produce low-affinity IgE (11). Note that by 15 weeks of HDM exposure, the pattern of elevated cytokines found in circulation is different from that found at 4 weeks. In addition, extensive lung remodeling is observed at 15 weeks but not at 4 weeks (22). It is also therefore possible that differences in availability of cytokines and chemokines at 4 weeks versus 15 weeks of HDM exposure may play an important role in the ability of IgE+ PCs cells to develop, migrate to the BM, and persist there.

In humans, numerous clinical observations suggest the existence of long-lived IgE+ BMPCs in atopic patients. For example, immediate anaphylaxis can be induced by allergens or drugs (e.g., penicillin) years after the initial sensitization, and even in the absence of allergen reexposure, persistent allergen-specific IgE production is maintained in allergic patients (1214). Accidental transfer of allergies and allergen-specific IgE production after BM transplants from atopic donors also suggests that IgE+ PCs exist in the BM of allergic patients (15, 16). Therapeutic agents that target IgE class switching, such as IL-4 and/or IL-13 blockade, are unable to lower serum IgE back to baseline (1720). Quilizumab, an antibody that targets the membrane-proximal (M1) domain of human IgE, has been shown to efficiently target IgE+ B cells and short-lived PCs in patients but was unable to deplete IgE+ BMPCs (19). Unexpectedly, serum IgE in quilizumab-treated patients was only reduced by ~20 to 30%, suggesting that >70% of IgE is produced by long-lived IgE+ PCs (19).

One lingering question about modeling IgE responses in mice is how faithfully the findings represent what happens in humans. In this study, we demonstrate that IgE+ PCs reside in the BM of atopic donors, and we directly demonstrate that allergen-specific IgE can be produced by these cells. BMPCs from two donors with different allergic profiles produce IgE that can induce mast cell degranulation in FcRI humanized mice in response to their respective allergens, a direct indication that IgE+ BMPCs contribute to IgE serological memory in atopic patients. Our ability to induce passive anaphylaxis in mice with IgE generated from either human BMPCs or from chronically HDM-exposed mice is indicative of the potential pathogenicity of these cells in both species.

Our findings highlight a population of IgE-producing cells that is highly relevant in the pathophysiology of allergic disorders and which, once generated, appears largely resistant to currently available targeted therapies for allergic disorders. Efforts to further characterize these cells will be necessary to devise strategies to target them in ways that could improve on currently available therapies.

To study the IgE response in vivo, we used an HDM-driven lung inflammation model in WT and membrane IgEvenus/Blimp-1mCherry single or dual reporter mice. Cellular responses were tracked by harvesting lymphoid tissues from the mice at the end of each experiment and analyzing them by flow cytometry. Molecular readouts were assessed using prepared RNA from harvested cells. Serum readouts, such as IgE or IgG1 levels, were assessed using ELISA. Pathogenicity of serum IgE derived from short-term and chronic HDMexposed mice was determined by PCA and PSA assays. The human IgE response was also examined ex vivo using BM samples from allergic and nonallergic donors. Human IgE-producing BMPCs were quantified using intracellular IgE staining, secretion of IgE was determined by ELISA from cultured BM supernatants, and the capacity of the IgE to induce anaphylaxis was determined by PCA. Statistical significance was calculated using GraphPad Prism.

All procedures were conducted in compliance with protocols approved by the Institutional Animal Care and Use Committee of Regeneron Pharmaceuticals. All mice used in this study were generated in a hybrid 129S6/C57BL/6 background. Previously described strategies were used to generate IgEVenus (9) and Blimp-1mCherry (28) reporter mice. Briefly, the coding sequence of Venus (yellow fluorescent reporter) was inserted downstream of the last membrane IgE exon (M2), linked by the ribosomal skipping porcine teschovirus-1 (P2A) (52) sequence to allow simultaneous expression of Venus with membrane IgE. Both endogenous membrane IgE polyadenylation sites were left intact. The coding sequence of mCherry was inserted at the 3 end of exon 7 in Prdm-1 (Blimp-1) gene linked by P2A. Self-deleting technology was used to remove the hygromycin or neomycin cassettes before phenotypic analysis of both reporters. VelociGene and VelociMouse methods (5356) were used to generate heterozygous (57) reporter mice. Blimp1mcherry F0 mice (50% B6/50% 129) were crossed to C57BL/6 mice to obtain F1 heterozygotes (75% B6/25% 129); IgEVenus F0 mice (50% B6/50% 129) were crossed to C57BL/6 mice to obtain F1 heterozygotes (75% B6/25% 129). Double reporter mice were generated by crossing F1 generations of IgEVenus heterozygous and Blimp-1mCherry heterozygous mice. All experiments were performed using IgEVenus homozygous and Blimp-1mCherry heterozygous mice unless otherwise indicated. For FcRI humanization, the mouse Fcer1a locus, located on mouse chromosome 1, was humanized by construction of unique targeting vectors from human and mouse bacterial artificial chromosomes DNA using VelociGene technology (5356).

In some experiments (Figs. 1, A and B, and 3A and figs. S1 and S3C), mice with IL-33 humanized locus (Il33hu/hu) were used. The IgE response in this background is comparable with WT (hybrid 129S6/C57BL/6) mice (23), and experiments performed in this background have been repeated in WT or in IgEVenus/Blimp-1mCherry reporter mice for consistency.

Mice were exposed to 50 g of HDM extract (Greer) diluted in 20 l of saline solution intranasally three times per week for either 4 or 15 weeks. Saline (20 l) was administered intranasally in control mice. For rest experiments, the dose of HDM was lowered to 25 g. At the end of the experiment, blood was collected for determination of serum concentrations of total IgE and HDM-specific IgG1, and spleen and BM were collected for flow cytometry.

Spleens were collected and mashed on 12-well, 70-m filter plates (Corning Costar) in RPMI 1640 media to generate single cell suspensions. For BM extraction, femurs were cut at both ends, placed in a PCR plate with holes punched at the bottom, and spun down for 3 min at 500g. RBC lysis was performed on single cell suspensions from spleen and BM, and samples were labeled with LIVE/DEAD solution (Thermo Fisher Scientific) for 10 min in the dark at room temperature (RT). Cells were then blocked using Fc Block (Tongo Biosciences) for 15 to 30 min at 4C, followed by incubation with a primary (surface) antibody mix for 30 min at 4C in Brilliant Stain Buffer (BD Biosciences). Samples were washed, fixed (BD Cytofix; 1:4 diluted), and run on autoMACS running buffer (Miltenyi Biotech). For intracellular staining, samples were fixed and permeabilized (BD Cytofix/Cytoperm and BD Perm/Wash buffer) and resuspended in intracellular mix for 30 min at 4C in the dark.

Single cell suspensions from BM were prepared from two to five mice in each group, and samples were pooled to generate enough cells for sequencing. Cells were stained with LIVE/DEAD dye, blocked with Fc Block, and stained with Ly6G, TCR, CD11b, CD49b, and CD117 (see antibody table) for dump gating and CD138 for PC gating. In Blimp-1mCherry reporter mice, PCs were sorted on the basis of Blimp-1mCherry expression on MoFlo Astrios (Beckman Coulter). All protocols for RNA extraction and sequencing library preparation were similar to those described previously (58). IgE and other Ig transcripts were mapped to mouse reference genome B38, with GENCODE V19.

Whole blood was collected into Microtainer SST serum tubes and pelleted by centrifuging at 15,000g for 10 min at 4C. For mice, serum samples were used to determine total IgE concentrations by IgE sandwich ELISA OptEIA kit (BD Biosciences) according to the manufacturers instructions. For human IgE ELISA, serum and BM supernatant were used to measure total IgE concentration using Human IgE ELISAPRO kit (Mabtech). Data analysis was performed using GraphPad Prism (GraphPad Software).

IgE ELISpots on human BM cells were performed following the manufacturers instructions (Mabtech) with few modifications. Briefly, ELISpot plates (Millipore) were coated with capture antibody (15 g/ml) in phosphate-buffered saline overnight. Plates were washed and blocked with media containing 10% fetal bovine serum. BM samples were added to each well (500 K per well), and plates were incubated at 37C overnight. Plates were washed, and IgE detection antibody (1 g/ml) was added for 2 hours at RT. Plates were washed and incubated with Streptavidin-alkaline phosphatase (ALP) for 1 hour. Spots were developed by adding 100 l of 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) plus substrate (Mabtech).

Human cat-allergic and nonallergic donor BM mononuclear cells and matching donor sera were obtained from HemaCare (Los Angeles, CA). Allergy status of each donor sera was checked by ImmunoCAP rapid test (Phadia, Thermo Fisher Scientific) following the manufacturers instructions. Serum and BM supernatant samples were also sent to Phadia Immunology Reference Laboratory (Portage, MI) for ImmunoCAP analysis to determine the concentration of cat-specific IgE levels.

For culturing human BM mononuclear cells in vitro, frozen samples were thawed at 37C for 3 min and washed in MarrowMAX BM media (Thermo Fisher Scientific). Cells were incubated in media that contains deoxyribonuclease I (0.1 mg/ml) (Roche) for 15 min at RT and washed twice. Samples were resuspended in MarrowMAX media and plated in six-well plates for 8 days.

PCA was performed as described previously (59). For sensitization, ears of nave mice received 10-l intradermal injection of sera derived from either HDM-exposed mice or saline-exposed controls. All sera were normalized to 25 ng of total IgE/10 l intradermal sensitization. After 24 hours, the mice were challenged by intravenous injection of 1 g of Der p 1 (Indoor Biotechnologies) diluted in 0.5% Evans blue dye (Sigma-Aldrich). One hour after allergen challenge, mice were euthanized, and Evans blue dye was extracted from ear tissue and spectrophotometrically quantitated using a standard curve (59).

For validation of FcRI humanized mice, groups of nave Fcer1ahu/hu mice were sensitized with a cocktail of two allergen-specific human IgE antibodies or an irrelevant IgG antibody (negative control) into the right and left ears, respectively. For PCA using human sera and BM supernatants, 10 l of neat sera or concentrated BM supernatants were used to sensitize ears of nave Fcer1ahu/hu mice.

For PSA sensitization, mice received an intravenous injection of sera derived from either HDM-exposed mice or saline-exposed controls (IgE concentration/dilution for each experiment indicated in figure captions). Fcer1ahu/hu mice were sensitized with a cocktail of two allergen-specific human IgE antibodies (0.5 g total) or an irrelevant IgG antibody (5 g total). After 24 hours, basal core temperature measurements were taken for all mice, followed by intravenous injection of 1 g of Fel d 1. Core temperature measurements were taken at the indicated time points after the allergen challenge and graphed as changes in core temperature at each time point relative to basal temperature. Histamine ELISA was performed on plasma of mice following the manufacturers protocol (Immuno-Biological Laboratories)

Single cell suspensions from BM or spleen were prepared from five to seven mice, and samples were pooled to analyze IgE switch junction sequences. S-S junction sequences were amplified as described previously (34). Briefly, DNA from each sample was prepared using DNeasy kit (QIAGEN) following the manufacturers protocol. S-S PCR was set up using Advantage 2 PCR (Takara) with the following primers: S forward primer, ACTCAGTCAGTCAGTGGCGTGAAGGGCT; S reverse primer, CATCAGGCTTTGCTCACTCA. Amplification was performed at 95C for 1 min, 35 cycles of 95C for 30 s, 68C for 4 min, and a final cycle of 68C for 4 min. PCR products were checked on a 1% agarose gel, purified, and cloned into pGEM-T cloning vector (Promega) following the manufacturers instructions. The ligation products were transformed into TOP10F competent cells (Invitrogen) for blue/white selection. Ninety-five white colonies were selected for each group for sequencing with T7 forward and M13 reverse primers. Sequenced inserts that contained both S-S sequences were analyzed, and the selected clone sequences were aligned to the 49-bp S1 switch region repeat using EMBOSS pairwise sequence alignment. Clones with alignment score above 50 were marked positive for S1 remnant.

Statistical and graphical analyses were performed using GraphPad Prism software (version 7.0). Normality was determined by Shapiro-Wilk normality test. One-way analysis of variance (ANOVA) or unpaired Students t test was used on normally distributed samples, and Mann-Whitney or Kruskal-Wallis tests were performed on samples that did not pass the normality test. Two-way ANOVA was used on experiments that had two independent variables. Results were considered statistically significant at P < 0.05.

See the rest here:
Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to serological memory - Science

IsoPlexis’ $20M Financing to Enable Continued Commercial Expansion of its Single-Cell Platforms – Clinical OMICs News

Single-cell functional proteomics platform developer IsoPlexis announced this week it has raised an additional $20 million in a Series C round, capital that will enable the company to continue the global expansion of its flagship IsoLight single-cell proteomic analysis platform.

The financing round comes as IsoPlexis pushes to expand its operational, manufacturing, and commercial team globally. Currently, the company has operations in the U.S., Europe, and Asia, with more than 130 employees.

According to the company, its technology has been used in a number of different settings including precision drug discovery and biomarker discovery in oncology, to identify proteomic differences that are often undetectable via other methods.

From confirming gene edits to pinpointing the biological drivers of response, leading researchers from both academic and biopharma are utilizing the IsoLight to solve challenges in cancer immunology, inflammatory diseases, and engineered cell therapy discovery and development, Sean Mackay, CEO and co-founder of IsoPlexis told Clinical OMICs. Using our high-dimensional data from each cell, researchers are improving their processes as theyre advancing development of their therapies towards achieving the most potent functional responses for improved outcomes in patients.

In 2020, Mackay said the company will continue to expand its applications and release innovative products addressing high need research areas for its existing and future customer base. This includes bolstering its technology to the ability to better understand the functional states of innate cell types such as NK cells and monocytes, and the roles these play in the immune system.

Additionally, well be introducing products to assess functional interactions within the phosphoproteomic and metabolomic landscapes, Mackay added. It is critical to have single-cell proteomic tools to understand these functional interactions to better tune cells and understand how gene edits functionally affect downstream signaling cascades to continue to make improvements within a variety of indications.

The recent financing was led by Northpond Ventures, along with participation from existing investors and brings to $45 million the total raised to date by IsoPlexis.

We are excited to continue our partnership with our investor base and to broaden our commercial impact globally with our single-cell proteomic systems. Our leadership in providing meaningful cellular insights to the world of cancer immunology, has rapidly translated to broad uptake for our solutions, Mackay noted in a press release.

IsoPlexis is providing much needed solutions to significant challenges in cancer, immunology, and engineered cellular therapy discovery and development, said Sharon Kedar, co-founder and partner of Northpond Ventures, in a statement. We are excited to continue partnering with IsoPlexis on these efforts to transform personalized medicine.

Read the original:
IsoPlexis' $20M Financing to Enable Continued Commercial Expansion of its Single-Cell Platforms - Clinical OMICs News

Type of Herpes Virus Tied to Multiple Sclerosis – The Scientist

As early as the 1990s, researchers proposed that a very common type of herpes virusthen known as human herpesvirus 6 (HHV6)could be somehow involved in the development of multiple sclerosis, a neurodegenerative disease characterized by autoimmune reactions against the protective myelin coating of the central nervous system.

However, the association between HHV6 and the disease soon became fraught with controversy as further studies produced discordant results. Complicating matters further, HHV6 turned out to be two related, but distinct variantsHHV6A and HHV6B. Because the two viruses are similar, for a while no method existed to tell whether a patient had been infected with one or the other, or bothmaking it difficult to draw a definitive association between either of the viruses and the disease.

I hope we rewoke the interest in this virus.

Anna Fogdell-Hahn, Karolinska Institute

Now, a collaboration of European researchers has developed a technique capable of distinguishing antibodies against one variant from the other. Using that method in a Swedish cohort of more than 8,700 multiple sclerosis patients and more than 7,200 controls, they found that patients were much more likely to carry higher levels of anti-HHV6A antibodies than healthy people, while they were likelier to carry fewer antibodies against HHV6B. The findings, published last November in Frontiers in Immunology, hint that previous contradictory results may at least be partially explained by the fact that researchers couldnt distinguish between the two viruses.

This article now makes a pretty convincing case that it is HHV6A that correlates with multiple sclerosis, and not HHV6B, remarks Margot Mayer-Prschel, a neuroscientist at the University of Rochester Medical Center who wasnt involved in the study. Researchers can now focus on one of these viruses rather than looking at [both] of them together.

HHV6A and HHV6B are two of eight herpesviruses known to infect people. More is known about the HHV6B variant, which most people catch as infants. It causes a brief rash-fever illness known as roseola. Both viruses typically fall dormant after the initial infection, sometimes re-activating later in life. Luckily for researchers, antibodies against them linger in the blood well into adulthood.

Through a careful analysis of the two viruses, researchers at the German Cancer Research Center in Heidelberg were able to identify a particular proteinknown as immediate-early protein 1 (IE1)that differed between the two variants.

Along with other research groups, they turned to a cohort of 8,742 Swedish multiple sclerosis patients who were enrolled in long-term studies of the disease and whose blood serum had been collected at the Karolinska Institute. They measured serum concentrations of antibodies for the IE1 protein, and then compared them with antibody concentrations in a cohort of 7,215 healthy, age-matched control individuals. Their analysis revealed that a positive association between HHV6A antibody concentrations and multiple sclerosis, whereas there was a negative association between HHV6B antibody levels and the disease.

The team also examined the relationship between the HHV6A antibody concentrations and other known risk factors for multiple sclerosis, including the presence of antibodies against another herpesvirus called Epstein-Barr virus (EBV). Interestingly, individuals who carried high levels of antibodies against both EBV and HHV6A were more even more likely to have been diagnosed with multiple sclerosis than those who carried high levels of anti-HHV6A antibodies alone, suggesting a possible interplay between the two pathogens. The team also found a relationship with known genetic risk factors for the disease.

It seems like there is an interaction with the other risk factors, says coauthor Anna Fogdell-Hahn, a neuroimmunologist at the Karolinska Institutes Center for Molecular Medicine. To her, the findings bolster the notion that it is a confluence of multiple factors that leads to the disease, and that HHV6A might be one of them.

How HHV6A might trigger or contribute to the disease is unclear, but Fogdell-Hahn has some theories shes planning on exploring in future research. While both HHV6A and HHV6B infect neurons, HHV6A differs in that it infects oligodendrocytes, the cells that generate the protective myelin sheath around neurons and are thought to be targeted by the autoimmune reactions of multiple sclerosis. When HHV6A reactivates and proliferates, it could borrow particular proteins from its oligodendrocyte host cells, Fogdell-Hahn speculates. And when certain immune cells then catch the pathogen and present the virus proteins to other immune cells, they might mistakenly present the bodys own oligodendrocyte proteins, and thereby trigger autoimmune reactions, she speculates.

Treatments exist for multiple sclerosis, but they all work by suppressing the immune system, leaving patients more vulnerable to other infections, Fogdell-Hahn notes. We should not give up the ambition to try to really understand what starts the disease, she says.

Steven Jacobson, the chief of the viral immunology section at the National Institute of Neurological Disorders and Stroke, who has collaborated with Fogdell-Hahn in the past but wasnt involved in the current study, is impressed by the sheer size of the study, which gives the findings statistical power. Very few of us have done studies in 15,000 . . . individuals. That to me is a real strength, he says. Without such large numbers, its difficult to uncover firm associations between relatively rare diseases and viruses that nearly everyone carries.

One important question, he notes, is whether HHV6A is simply reactivated as a result of the inflammatory symptoms of multiple sclerosis, rather than a contributor to the disease. To Mayer-Prschel, some of the teams results hint at a contributing role. In a separate analysis based on a different cohort of patients whose blood samples had been taken before they developed the disease, the researchers found higher concentrations of anti-HHV6A antibodies compared to control individuals who never developed the disease. If reactivation of HHV6A were a mere consequence of the disease, one would expect patients at the most advanced stages to have the highest antibody response. However, it was exactly opposite: the youngest patients who had not yet [developed] the pathology had a very robust HHV6A-specific [antibody] response. I thought that was enlightening, says Mayer-Prschel.

Still, one would need an interventional study to prove a causative role for the virus, Jacobson saysfor instance by blocking the virus and investigating whether the patients symptoms improve. But thats easier said than done, he notes. There are really not very great antiviral drugs out there, and its almost a catch 22 [situation where] you need the antiviral drug to show this effect on the disease, but until you show that the virus has something to do with the disease, no one is going to make the antiviral drug. Nevertheless, the new research is a step in the right direction, he notes.

The biggest effect of the study, Mayer-Prschel says, is that it may attract further funding to studying HHV6Aa field some say has been largely neglected by funding bodies. Fogdell-Hahn agrees. I hope we rewoke the interest in this virus, she says. Theres so many things that we want to do.

E. Engdahl et al., Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis, Frontiers in Immunology, doi:10.3389/fimmu.2019.02715, 2019.

Katarina Zimmer is a New Yorkbased freelance journalist. Find her on Twitter @katarinazimmer.

Original post:
Type of Herpes Virus Tied to Multiple Sclerosis - The Scientist

U-M researchers find new function for macropinocytosis in mammalian cell growth – Michigan Medicine

For the first time, researchers at Michigan Medicine have demonstrated that a cellular process known to be involved in cancer and other diseases also plays an important role in the growth of at least one type of normal mammalian cell.

Macropinocytosis is an ancient process by which cells take in large volumes of material from outside of themselves. The process is hijacked by certain cancer cells to gather proteins to break down into cellular fuel. The process is also exploited by viruses and bacteria to enter cells.

New findings from the lab of Philip D. King, Ph.D., professor of Microbiology & Immunology at the U-M Medical School and a member of the U-M Rogel Cancer Center, showed that both primary mouse and human T cells which play a central role in the immune response engage in macropinocytosis to support normal cell growth.

Our research suggests that this may be a more general phenomenon, applicable to the growth of other primary cell types, says study lead author John Charpentier, a graduate student in Kings lab.

King adds, Blocking macropinocytosis in cancer might not represent an effective means of treating cancer since it is predicted that the generation of an anti-tumor T cell immune response would also be inhibited using this approach.

Paper cited: Macropinocytosis drives T cell growth by sustaining the activation of mTORC1, Nature Communications. DOI: 10.1038/s41467-019-13997-3

View original post here:
U-M researchers find new function for macropinocytosis in mammalian cell growth - Michigan Medicine

OncoMyx Therapeutics Announces Formation of Scientific Advisory Board – Arizona Daily Star

This is a group of highly-accomplished scientists and drug hunters, some whom I have known for many years, said Leslie Sharp, Ph.D., chief scientific officer (CSO) of OncoMyx. We are thrilled to welcome Tobias, Neil, Grant, Ronan, and Dominic to our SAB, and I look forward to working with the team to develop new therapeutic options for cancer patients.

The SAB will be comprised of the following members:

Tobias Bald, Ph.D. is the Head of the Oncology and Cellular Immunology Laboratory at QIMR Berghofer Medical Research Institute. He is a leading expert in tumor immunology with a strong focus on the role of the innate immune system during tumor development, progression and cancer immunotherapy.

Neil Gibson, Ph.D. is President and CEO of PDI Therapeutics and Senior Vice President of COI Pharmaceuticals. Dr. Gibson has more than 30 years of drug development experience and has been involved in the successful discovery, development and commercialization of four approved oncology drugs (including temozolomide, sorafenib, erlotnib, and crizotinib). Dr Gibsons extensive oncology experience includes being CSO of Pfizer Oncology Research Unit, CSO of Regulus Therapeutics and CSO of OSI Pharmaceuticals. Dr. Gibson also serves on the board of TCR2, a new public company focused on T-cell therapies.

Follow this link:
OncoMyx Therapeutics Announces Formation of Scientific Advisory Board - Arizona Daily Star